[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 31845
1. Mitchell G, Girgis A, Jiwa M, Sibbritt D, Burridge L: A GP Caregiver Needs Toolkit versus usual care in the management of the needs of caregivers of patients with advanced cancer: a randomized controlled trial. Trials; 2010;11:115
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A GP Caregiver Needs Toolkit versus usual care in the management of the needs of caregivers of patients with advanced cancer: a randomized controlled trial.
  • BACKGROUND: Caring for a person with progressive cancer creates challenges for caregivers.
  • This paper outlines a study protocol aimed at developing and evaluating the effectiveness of a general practice-based intervention to better meet the needs of caregivers of patients with advanced cancer.
  • METHODS/DESIGN: Two hundred and sixty caregivers will be randomised into each of two arms of the intervention (520 participants in total) through patients with advanced cancer attending medical and radiation oncology outpatient clinics at two tertiary hospital sites.
  • DISCUSSION: This study will determine whether systematic assessment of caregiver needs supported by caregiver-specific information for General Practitioners is effective in alleviating the unmet needs experienced by caregivers caring for patients with advanced cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pain Symptom Manage. 1999 Jun;17(6):418-28 [10388247.001]
  • [Cites] J Palliat Med. 2003 Dec;6(6):911-8 [14733683.001]
  • [Cites] Palliat Med. 2005 Oct;19(7):551-5 [16295288.001]
  • [Cites] Eur J Cancer Care (Engl). 2006 May;15(2):163-71 [16643264.001]
  • [Cites] Palliat Med. 2008 Dec;22(8):904-12 [18772208.001]
  • [Cites] Palliat Med. 2008 Dec;22(8):956-64 [18952754.001]
  • [Cites] J Eval Clin Pract. 2009 Aug;15(4):602-6 [19522727.001]
  • [Cites] Psychooncology. 2010 Jul;19(7):726-33 [19777532.001]
  • [Cites] Palliat Med. 2003 Jan;17(1):63-74 [12597468.001]
  • [Cites] Palliat Med. 2003 Jan;17(1):27-39 [12597463.001]
  • [Cites] J Pain Symptom Manage. 2002 Aug;24(2):91-6 [12231124.001]
  • [Cites] Hematol Oncol Clin North Am. 2002 Jun;16(3):745-62, xi [12170579.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3219-25 [11432889.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):217-25 [10618626.001]
  • [Cites] Palliat Med. 1994;8(3):183-96 [7952369.001]
  • [Cites] Acta Psychiatr Scand. 1983 Jun;67(6):361-70 [6880820.001]
  • [Cites] CMAJ. 2004 Jun 8;170(12):1795-801 [15184333.001]
  • [Cites] J Palliat Med. 2004 Feb;7(1):19-25 [15008126.001]
  • [Cites] Psychooncology. 2011 Apr;20(4):387-93 [20878835.001]
  • [Cites] Med Care. 2003 Aug;41(8):992-1001 [12886178.001]
  • [Cites] Psychooncology. 2005 Jun;14(6):492-502 [15452896.001]
  • (PMID = 21114863.001).
  • [ISSN] 1745-6215
  • [Journal-full-title] Trials
  • [ISO-abbreviation] Trials
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN43614355
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3009964
  •  go-up   go-down


2. Derici H, Yaman I, Tansug T, Nazli O, Bozdag AD, Isguder AS: Prognostic Factors of Patients With Transmural Advanced Gastric Carcinoma. Gastroenterology Res; 2009 Dec;2(6):317-323

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic Factors of Patients With Transmural Advanced Gastric Carcinoma.
  • BACKGROUND: The purpose of this study is to evaluate perioperative morbidity, mortality and the prognostic factors that influence survival of the patients with transmural advanced gastric carcinoma after curative surgical therapy.
  • METHODS: Fifty patients with transmural advanced gastric adenocarcinoma underwent curative resection in our clinic.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27990200.001).
  • [ISSN] 1918-2805
  • [Journal-full-title] Gastroenterology research
  • [ISO-abbreviation] Gastroenterology Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Advanced / Gastric Cancer / Morbidity / Mortality / Survival / Transmural
  •  go-up   go-down


3. Macciò A, Madeddu C, Gramignano G, Mulas C, Sanna E, Mantovani G: Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study. Oncologist; 2010;15(8):894-902
MedlinePlus Health Information. consumer health - Anemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study.
  • Advanced-stage cancer patients often suffer from anemia that closely resembles the anemia of chronic inflammatory diseases characterized by specific changes in iron homeostasis and absorption. i.v. iron improves the efficacy of recombinant human erythropoietin (rHuEPO) in anemic cancer patients undergoing chemotherapy.
  • We report the results of an open-label, randomized, prospective trial aimed at testing the efficacy and safety of treatment with oral lactoferrin versus i.v. iron, both combined with rHuEPO, for the treatment of anemia in a population of 148 advanced cancer patients undergoing chemotherapy.
  • In conclusion, these results show similar efficacy for oral lactoferrin and for i.v. iron, combined with rHuEPO, for the treatment of anemia in advanced cancer patients undergoing chemotherapy.

  • Genetic Alliance. consumer health - Anemia.
  • Genetic Alliance. consumer health - Oral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2009 May 2;373(9674):1532-42 [19410717.001]
  • [Cites] Biochem Pharmacol. 2009 May 15;77(10):1572-9 [19174153.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2840-6 [10561360.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2214-21 [11413508.001]
  • [Cites] Haematologica. 2002 Nov;87(11):1209-21 [12414352.001]
  • [Cites] Blood. 2003 Aug 1;102(3):783-8 [12663437.001]
  • [Cites] Lancet. 2003 Oct 18;362(9392):1255-60 [14575968.001]
  • [Cites] Semin Oncol. 2003 Oct;30(5 Suppl 16):174-84 [14613039.001]
  • [Cites] Am J Med. 2004 Apr 5;116 Suppl 7A:11S-26S [15050883.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1301-7 [15051778.001]
  • [Cites] J Clin Invest. 2004 May;113(9):1251-3 [15124013.001]
  • [Cites] Int J Cancer. 2004 Sep 1;111(3):398-403 [15221967.001]
  • [Cites] Biometals. 2004 Jun;17(3):209-16 [15222467.001]
  • [Cites] N Engl J Med. 1990 Jun 14;322(24):1689-92 [2342534.001]
  • [Cites] Blood. 1992 Oct 1;80(7):1639-47 [1391934.001]
  • [Cites] J Natl Cancer Inst. 1999 Oct 6;91(19):1616-34 [10511589.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):1011-23 [15758012.001]
  • [Cites] Blood. 2005 Jul 1;106(1):362-7 [15774616.001]
  • [Cites] Oncologist. 2005 Jun-Jul;10(6):438-48 [15967837.001]
  • [Cites] Nat Rev Cancer. 2005 Jul;5(7):543-55 [15965494.001]
  • [Cites] Stem Cells Dev. 2005 Oct;14(5):548-55 [16305339.001]
  • [Cites] Am J Clin Nutr. 2006 Feb;83(2):305-9 [16469988.001]
  • [Cites] Oncologist. 2007 Feb;12(2):231-42 [17296819.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1601-10 [17332307.001]
  • [Cites] Lancet. 2007 May 5;369(9572):1502-4 [17482969.001]
  • [Cites] J Clin Oncol. 2008 Jan 1;26(1):132-49 [17954713.001]
  • [Cites] JAMA. 2008 Feb 27;299(8):914-24 [18314434.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1611-8 [18375890.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1619-25 [18375891.001]
  • [Cites] J Natl Compr Canc Netw. 2008 Jul;6(6):536-64 [18597709.001]
  • [Cites] Cancer. 2008 Sep 15;113(6):1480-8 [18642348.001]
  • [Cites] Int J Antimicrob Agents. 2009 Apr;33(4):301.e1-8 [18842395.001]
  • [Cites] Semin Arthritis Rheum. 2009 Apr;38(5):382-8 [18336871.001]
  • [Cites] J Clin Oncol. 2009 Sep 1;27(25):4217-26 [19636005.001]
  • (PMID = 20647390.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ferric Compounds; 0 / Hemoglobins; 0 / Recombinant Proteins; 11096-26-7 / Erythropoietin; 88088-23-7 / ferric gluconate; EC 3.4.21.- / Lactoferrin
  • [Other-IDs] NLM/ PMC3228020
  •  go-up   go-down


Advertisement
4. Kutner JS, Smith MC, Corbin L, Hemphill L, Benton K, Mellis BK, Beaty B, Felton S, Yamashita TE, Bryant LL, Fairclough DL: Massage therapy versus simple touch to improve pain and mood in patients with advanced cancer: a randomized trial. Ann Intern Med; 2008 Sep 16;149(6):369-79
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Massage therapy versus simple touch to improve pain and mood in patients with advanced cancer: a randomized trial.
  • OBJECTIVE: To evaluate the efficacy of massage for decreasing pain and symptom distress and improving quality of life among persons with advanced cancer.
  • PATIENTS: 380 adults with advanced cancer who were experiencing moderate-to-severe pain; 90% were enrolled in hospice.
  • The generalizability to all patients with advanced cancer is uncertain.
  • CONCLUSION: Massage may have immediately beneficial effects on pain and mood among patients with advanced cancer.

  • MedlinePlus Health Information. consumer health - Pain.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Nurs. 2000 Oct;23(5):327-36 [11037952.001]
  • [Cites] AACN Clin Issues. 2000 Feb;11(1):77-96 [11040555.001]
  • [Cites] Cancer. 2000 Oct 15;89(8):1854-65 [11042583.001]
  • [Cites] J Pain Symptom Manage. 2000 Nov;20(5):374-87 [11068159.001]
  • [Cites] Stat Med. 2001 Apr 15;20(7):1009-21 [11276032.001]
  • [Cites] Hosp J. 2000;15(3):31-53 [11315685.001]
  • [Cites] Emerg Med J. 2001 May;18(3):205-7 [11354213.001]
  • [Cites] J Pain Symptom Manage. 2001 Jun;21(6):473-80 [11397605.001]
  • [Cites] Cancer Nurs. 2001 Jun;24(3):180-4 [11409061.001]
  • [Cites] Palliat Med. 2001 Sep;15(5):363-71 [11591087.001]
  • [Cites] Eur J Pharmacol. 2001 Oct 19;429(1-3):1-11 [11698022.001]
  • [Cites] Complement Ther Nurs Midwifery. 2000 Nov;6(4):169-75 [11858299.001]
  • [Cites] J Palliat Med. 2002 Jun;5(3):397-406 [12133244.001]
  • [Cites] Palliat Med. 2003 Jun;17(4):300-7 [12822844.001]
  • [Cites] J Pain. 2003 Sep;4(7):407-14 [14622683.001]
  • [Cites] Integr Cancer Ther. 2003 Dec;2(4):332-44 [14713325.001]
  • [Cites] Palliat Med. 2004 Mar;18(2):87-92 [15046404.001]
  • [Cites] Cochrane Database Syst Rev. 2004;(2):CD002287 [15106172.001]
  • [Cites] J Psychosom Res. 2004 Jul;57(1):45-52 [15256294.001]
  • [Cites] J Palliat Med. 2004 Jun;7(3):405-7 [15265348.001]
  • [Cites] Nurs Res. 1986 Mar-Apr;35(2):101-6 [3633503.001]
  • [Cites] Cancer. 1987 Sep 1;60(5):1151-8 [3300951.001]
  • [Cites] World Health Organ Tech Rep Ser. 1990;804:1-75 [1702248.001]
  • [Cites] Holist Nurs Pract. 1991 Oct;6(1):24-31 [1918182.001]
  • [Cites] Cancer Nurs. 1993 Apr;16(2):93-101 [8477405.001]
  • [Cites] Ann Acad Med Singapore. 1994 Mar;23(2):129-38 [8080219.001]
  • [Cites] Qual Life Res. 1994 Jun;3(3):183-9 [7920492.001]
  • [Cites] Eur J Cancer. 1994;30A(9):1326-36 [7999421.001]
  • [Cites] Pain. 1995 May;61(2):277-84 [7659438.001]
  • [Cites] Ann Emerg Med. 1996 Apr;27(4):485-9 [8604867.001]
  • [Cites] J Pain Symptom Manage. 1996 Oct;12(4):209-20 [8898504.001]
  • [Cites] J Pain Symptom Manage. 1996 Nov;12(5):273-82 [8942122.001]
  • [Cites] Neurology. 1997 Feb;48(2):332-8 [9040716.001]
  • [Cites] Palliat Med. 1997 Jan;11(1):3-20 [9068681.001]
  • [Cites] J Pain Symptom Manage. 1997 May;13(5):254-61 [9185430.001]
  • [Cites] Cancer. 1998 Jul 1;83(1):173-9 [9655308.001]
  • [Cites] Support Care Cancer. 1998 Nov;6(6):539-41 [9833305.001]
  • [Cites] Am Psychol. 1998 Dec;53(12):1270-81 [9872050.001]
  • [Cites] JAMA. 1999 Jan 13;281(2):163-8 [9917120.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):361-70 [10458255.001]
  • [Cites] Cancer Invest. 2004;22(4):526-36 [15565810.001]
  • [Cites] Cancer Invest. 2004;22(5):678-87 [15581048.001]
  • [Cites] Cancer Control. 2005 Jul;12(3):186-95 [16062166.001]
  • [Cites] Palliat Support Care. 2003 Sep;1(3):231-7 [16594423.001]
  • [Cites] J Holist Nurs. 2006 Sep;24(3):152-61 [16880409.001]
  • [Cites] Clin Nurs Res. 2007 May;16(2):85-99; discussion 100-2 [17452429.001]
  • [Cites] J Pain Symptom Manage. 2007 Sep;34(3):227-36 [17572055.001]
  • [Cites] Health Qual Life Outcomes. 2007;5:51 [17683554.001]
  • [Cites] Ann Intern Med. 2008 Feb 19;148(4):W60-6 [18283201.001]
  • [Cites] Ann Intern Med. 2008 Feb 19;148(4):295-309 [18283207.001]
  • [Cites] J Soc Integr Oncol. 2008 Winter;6(1):19-28 [18302907.001]
  • [Cites] J Soc Integr Oncol. 2007 Fall;5(4):139-46 [19087757.001]
  • [Cites] Pain. 1999 May;81(1-2):129-34 [10353500.001]
  • [Cites] J Pain Symptom Manage. 1999 Jul;18(1):9-16 [10439568.001]
  • [Cites] J Pain Symptom Manage. 2004 Sep;28(3):244-9 [15336336.001]
  • [Cites] ANS Adv Nurs Sci. 1982 Jul;4(4):44-61 [6808905.001]
  • [Cites] ANS Adv Nurs Sci. 1984 Jan;6(2):42-9 [6322674.001]
  • [Cites] Lancet. 1985 May 25;1(8439):1204-6 [2860399.001]
  • [Cites] BMJ. 2000 Feb 19;320(7233):513-4 [10678876.001]
  • [Cites] Cancer. 2000 Sep 1;89(5):1162-71 [10964347.001]
  • [SummaryForPatientsIn] Ann Intern Med. 2008 Sep 16;149(6):I38 [18794554.001]
  • (PMID = 18794556.001).
  • [ISSN] 1539-3704
  • [Journal-full-title] Annals of internal medicine
  • [ISO-abbreviation] Ann. Intern. Med.
  • [Language] ENG
  • [Grant] United States / NCCIH NIH HHS / AT / 1R01AT0100601A2; United States / NCCIH NIH HHS / AT / R01 AT001006; United States / NCCIH NIH HHS / AT / AT001006-02; United States / NCCIH NIH HHS / AT / R01 AT001006-01A2; United States / NCCIH NIH HHS / AT / AT001006-03; United States / NCCIH NIH HHS / AT / R01 AT001006-03; United States / NCCIH NIH HHS / AT / AT001006-01A2; United States / NCCIH NIH HHS / AT / R01 AT001006-02
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS65966; NLM/ PMC2631433
  •  go-up   go-down


5. Torres-Vigil I, Aday LA, Reyes-Gibby C, De Lima L, Herrera AP, Mendoza T, Cleeland CS: Health care providers' assessments of the quality of advanced-cancer care in Latin American medical institutions: a comparison of predictors in five countries: Argentina, Brazil, Cuba, Mexico, and Peru. J Pain Palliat Care Pharmacother; 2008;22(1):7-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health care providers' assessments of the quality of advanced-cancer care in Latin American medical institutions: a comparison of predictors in five countries: Argentina, Brazil, Cuba, Mexico, and Peru.
  • This paper describes an innovative Pan-American survey on advanced-cancer care and examines the quality-of-care provided by Latin American institutions.
  • A convenience sample of 777 physicians and nurses who treat cancer patients in Argentina, Brazil, Cuba, Mexico, and Peru were surveyed.
  • Barring respondents from Cuba, providers from the other four nations who practice in public institutions rated the quality of advanced-cancer care in their own institutions lower than those practicing in private hospitals or specialized cancer centers.
  • Other institutional quality-of-care predictors included type of city, affordability-of-care ratings, availability of opioid analgesics, where patients die, barriers to cancer pain management, and the provider's specialty and gender.
  • These findings highlight the need for providing accessible care and services to improve the quality of advanced-cancer care in Latin American institutions.
  • Efforts should be aimed at improving the care offered in public institutions and addressing other types of disparities that may exist within countries by creating supportive and palliative cancer care programs that are accessible and affordable to those most in need.
  • [MeSH-minor] Argentina. Brazil. Cancer Care Facilities. Cuba. Disease Progression. Health Surveys. Hospitals, Private. Hospitals, Public. Humans. Latin America. Mexico. Peru. Practice Patterns, Physicians'

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19042817.001).
  • [ISSN] 1536-0539
  • [Journal-full-title] Journal of pain & palliative care pharmacotherapy
  • [ISO-abbreviation] J Pain Palliat Care Pharmacother
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Gagnon B, Low G, Schreier G: Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study. J Psychiatry Neurosci; 2005 Mar;30(2):100-7
Hazardous Substances Data Bank. METHYLPHENIDATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study.
  • OBJECTIVE: To investigate the clinical improvement observed in patients with advanced cancer and hypoactive delirium after the administration of methylphenidate hydrochloride.
  • METHODS: Fourteen patients with advanced cancer and hypoactive delirium were seen between March 1999 and August 2000 at the Palliative Care Day Hospital and the inpatient Tertiary Palliative Care Unit of Montreal General Hospital, Montreal.
  • CONCLUSIONS: Hypoactive delirium that cannot be explained by an underlying cause (metabolic or drug-induced) in patients with advanced cancer appears to be a specific syndrome that could be improved by the administration of methylphenidate.

  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • MedlinePlus Health Information. consumer health - Delirium.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Intern Med. 2000 Mar 27;160(6):786-94 [10737278.001]
  • [Cites] Rinsho Shinkeigaku. 1999 May;39(5):555-9 [10424149.001]
  • [Cites] Brain. 2000 Jul;123 ( Pt 7):1481-94 [10869059.001]
  • [Cites] Mayo Clin Proc. 2000 Jul;75(7):711-21 [10907387.001]
  • [Cites] J Pain Symptom Manage. 2000 Jun;19(6):412-26 [10908822.001]
  • [Cites] Eur J Nucl Med. 2000 Oct;27(10):1518-24 [11083541.001]
  • [Cites] J Neurosci. 2001 Feb 15;21(4):1413-9 [11160413.001]
  • [Cites] Am J Hosp Palliat Care. 2001 Nov-Dec;18(6):403-7 [11712722.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):335-9 [11773187.001]
  • [Cites] J Neurosci. 2002 Oct 1;22(19):8705-10 [12351745.001]
  • [Cites] Ann Nucl Med. 2002 Dec;16(8):527-31 [12593417.001]
  • [Cites] Neurosci Biobehav Rev. 2003 Nov;27(7):615-21 [14624806.001]
  • [Cites] J Psychiatr Res. 1975 Nov;12(3):189-98 [1202204.001]
  • [Cites] Can J Psychiatry. 1984 Feb;29(1):46-9 [6704886.001]
  • [Cites] Head Neck Surg. 1986 Mar-Apr;8(4):296-300 [3744858.001]
  • [Cites] N Engl J Med. 1989 Mar 2;320(9):578-82 [2644535.001]
  • [Cites] J Pain Symptom Manage. 1989 Mar;4(1):3-6 [2703735.001]
  • [Cites] Am J Psychiatry. 1990 Jan;147(1):22-30 [2403472.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1990 Dec;53(12):1084-8 [1963440.001]
  • [Cites] Support Care Cancer. 1995 Mar;3(2):135-8 [7539701.001]
  • [Cites] Int J Psychiatry Med. 1995;25(1):1-19 [7649714.001]
  • [Cites] Int J Psychiatry Med. 1995;25(1):53-67 [7649718.001]
  • [Cites] Psychosomatics. 1995 Sep-Oct;36(5):471-9 [7568655.001]
  • [Cites] J Neuropsychiatry Clin Neurosci. 1995 Summer;7(3):347-50 [7580196.001]
  • [Cites] Psychosomatics. 1996 Jan-Feb;37(1):57-62 [8600496.001]
  • [Cites] JAMA. 1996 Mar 20;275(11):852-7 [8596223.001]
  • [Cites] Psychiatr Clin North Am. 1996 Sep;19(3):515-47 [8856815.001]
  • [Cites] Drug Saf. 1996 Oct;15(4):291-301 [8905254.001]
  • [Cites] Semin Oncol. 1997 Jun;24(3):318-28 [9208887.001]
  • [Cites] Brain. 1997 Jun;120 ( Pt 6):923-8 [9217677.001]
  • [Cites] Pathologe. 1997 Sep;18(5):406-10 [9432678.001]
  • [Cites] Neuropediatrics. 1998 Jun;29(3):159-62 [9706628.001]
  • [Cites] Arch Phys Med Rehabil. 1998 Sep;79(9):1047-50 [9749682.001]
  • [Cites] J Pain Symptom Manage. 1998 Sep;16(3):193-8 [9769622.001]
  • [Cites] Rev Neurol (Paris). 1998 Jul;154(6-7):539-41 [9773088.001]
  • [Cites] J Neurol. 1998 Nov;245(11):695-708 [9808237.001]
  • [Cites] N Engl J Med. 1999 Jun 10;340(23):1788-95 [10362822.001]
  • [Cites] J Formos Med Assoc. 1999 May;98(5):368-71 [10420707.001]
  • [Cites] Support Care Cancer. 2000 Mar;8(2):134-7 [10739361.001]
  • (PMID = 15798785.001).
  • [ISSN] 1180-4882
  • [Journal-full-title] Journal of psychiatry & neuroscience : JPN
  • [ISO-abbreviation] J Psychiatry Neurosci
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Central Nervous System Stimulants; 207ZZ9QZ49 / Methylphenidate
  • [Other-IDs] NLM/ PMC551162
  •  go-up   go-down


7. Kadan-Lottick NS, Vanderwerker LC, Block SD, Zhang B, Prigerson HG: Psychiatric disorders and mental health service use in patients with advanced cancer: a report from the coping with cancer study. Cancer; 2005 Dec 15;104(12):2872-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Psychiatric disorders and mental health service use in patients with advanced cancer: a report from the coping with cancer study.
  • BACKGROUND: Psychological morbidity has been proposed as a source of distress in cancer patients.
  • 1) determine the prevalence of diagnosable psychiatric illnesses, and 2) describe the mental health services received and predictors of service utilization in patients with advanced cancer.
  • METHODS: This was a cross-sectional, multi-institutional study of 251 eligible patients with advanced cancer.
  • RESULTS: Overall, 12% met criteria for a major psychiatric condition and 28% had accessed a mental health intervention for a psychiatric illness since the cancer diagnosis.
  • Cancer patients who had discussed psychological concerns with mental health staff (odds ratio [OR] = 19.2; 95% confidence interval [95% CI], 8.90-41.50) and non-Hispanic white patients (OR = 2.7; 95% CI, 1.01-7.43) were more likely to receive mental health services in adjusted analysis.
  • CONCLUSIONS: Advanced cancer patients experience major psychiatric disorders at a prevalence similar to the general population, but affected individuals have a low rate of utilizing mental health services.

  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • [Cites] JAMA. 1983 Feb 11;249(6):751-7 [6823028.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6899-907 [16129849.001]
  • [Cites] J Clin Oncol. 1985 Nov;3(11):1553-60 [4056846.001]
  • [Cites] Ann Intern Med. 1987 Oct;107(4):481-5 [3631786.001]
  • [Cites] Lancet. 1999 Oct 16;354(9187):1331-6 [10533861.001]
  • [Cites] Ann Intern Med. 2000 Feb 1;132(3):209-18 [10651602.001]
  • [Cites] Palliat Med. 1999 Jul;13(4):353-4 [10659105.001]
  • [Cites] Cancer. 2000 May 15;88(10):2398-424 [10820364.001]
  • [Cites] JAMA. 2000 Nov 15;284(19):2518-21 [11074786.001]
  • [Cites] JAMA. 2000 Dec 13;284(22):2907-11 [11147988.001]
  • [Cites] Ethn Dis. 2001 Winter;11(1):97-106 [11289258.001]
  • [Cites] Patient Educ Couns. 2001 Dec 1;45(3):195-8 [11722855.001]
  • [Cites] J Clin Psychiatry. 2001;62 Suppl 8:64-7 [12108825.001]
  • [Cites] Cancer. 2002 Jun 1;94(11):3006-15 [12115391.001]
  • [Cites] Hematol Oncol Clin North Am. 2002 Jun;16(3):671-700 [12170575.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2754-9 [12860955.001]
  • [Cites] Am J Hematol. 2003 Nov;74(3):224 [14587060.001]
  • [Cites] Semin Clin Neuropsychiatry. 2003 Oct;8(4):241-52 [14613051.001]
  • [Cites] Jpn J Clin Oncol. 2003 Oct;33(10):538-40 [14623924.001]
  • [Cites] Gen Hosp Psychiatry. 2004 Mar-Apr;26(2):121-8 [15038929.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1957-65 [15143090.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Jun;130(6):327-33 [15007642.001]
  • [Cites] J Natl Cancer Inst Monogr. 2004;(32):9-16 [15263035.001]
  • [Cites] J Natl Cancer Inst Monogr. 2004;(32):32-9 [15263039.001]
  • [Cites] J Natl Cancer Inst Monogr. 2004;(32):57-71 [15263042.001]
  • [Cites] J Natl Cancer Inst Monogr. 2004;(32):80-92 [15263046.001]
  • [Cites] J Natl Cancer Inst Monogr. 2004;(32):127-35 [15263054.001]
  • [Cites] Br J Cancer. 1991 Aug;64(2):349-52 [1892762.001]
  • [Cites] Int J Psychiatry Med. 1991;21(2):149-55 [1894454.001]
  • [Cites] Psychosomatics. 1991 Fall;32(4):420-5 [1961856.001]
  • [Cites] Arch Gen Psychiatry. 1992 Aug;49(8):630-6 [1637253.001]
  • [Cites] Eur J Cancer. 1993;29A(4):524-7 [8435204.001]
  • [Cites] Psychosomatics. 1993 May-Jun;34(3):208-21 [8493302.001]
  • [Cites] Palliat Med. 1993;7(3):213-8 [8261189.001]
  • [Cites] J Affect Disord. 1993 Oct-Nov;29(2-3):77-84 [8300980.001]
  • [Cites] Qual Life Res. 1994 Jun;3(3):183-9 [7920492.001]
  • [Cites] J Pain Symptom Manage. 1995 Feb;10(2):131-41 [7730685.001]
  • [Cites] Am J Psychiatry. 1995 Aug;152(8):1185-91 [7625468.001]
  • [Cites] N Engl J Med. 1996 Jul 18;335(3):172-8 [8657216.001]
  • [Cites] Soc Sci Med. 1996 Jun;42(11):1511-9 [8771634.001]
  • [Cites] Clin Geriatr Med. 1996 May;12(2):329-47 [8799351.001]
  • [Cites] Am J Psychiatry. 1997 Dec;154(12):1734-40 [9396954.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1594-600 [9552071.001]
  • [Cites] Psychosomatics. 1998 Jul-Aug;39(4):366-70 [9691706.001]
  • [Cites] Oncol Nurs Forum. 1999 Apr;26(3):593-9 [10214600.001]
  • [Cites] Palliat Med. 1999 Jan;13(1):45-50 [10320875.001]
  • [Cites] Br J Cancer. 1999 May;80(5-6):766-74 [10360654.001]
  • [Cites] Support Care Cancer. 2004 Sep;12(9):657-62 [15185134.001]
  • [Cites] Support Care Cancer. 2004 Dec;12(12):864-70 [15480816.001]
  • [Cites] Cancer. 1984 May 15;53(10 Suppl):2243-9 [6704912.001]
  • (PMID = 16284994.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA106370; United States / NCRR NIH HHS / RR / K12 RR017594; United States / NIA NIH HHS / AG / P30AG21342; United States / NIMH NIH HHS / MH / MH63892; United States / NCRR NIH HHS / RR / K12RR17594; United States / NIA NIH HHS / AG / P30 AG021342; United States / NIMH NIH HHS / MH / MH56529; United States / NCI NIH HHS / CA / R01 CA106370; United States / NIMH NIH HHS / MH / R01 MH063892
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS8305; NLM/ PMC1459283
  •  go-up   go-down


8. Loprinzi CL, Levitt R, Barton DL, Sloan JA, Atherton PJ, Smith DJ, Dakhil SR, Moore DF Jr, Krook JE, Rowland KM Jr, Mazurczak MA, Berg AR, Kim GP, North Central Cancer Treatment Group: Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial. Cancer; 2005 Jul 1;104(1):176-82
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial.
  • The basis for this popularity is the claim that sharks rarely get cancer because of the high proportion of cartilage in the shark's body.
  • Therefore, a clinical trial was conducted to look at the impact of shark cartilage in patients with advanced cancer.
  • The primary goal of this trial was to determine whether a shark cartilage product improved overall survival for patients with advanced cancer who were getting standard care.
  • CONCLUSION: This trial was unable to demonstrate any suggestion of efficacy for this shark cartilage product in patients with advanced cancer.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Complementary and Integrative Medicine.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15912493.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-35101; United States / NCI NIH HHS / CA / CA-35103; United States / NCI NIH HHS / CA / CA-35113; United States / NCI NIH HHS / CA / CA-35195; United States / NCI NIH HHS / CA / CA-35269; United States / NCI NIH HHS / CA / CA-35272; United States / NCI NIH HHS / CA / CA-35448; United States / NCI NIH HHS / CA / CA-37404; United States / NCI NIH HHS / CA / CA-37417; United States / NCI NIH HHS / CA / CA-52352; United States / NCI NIH HHS / CA / CA-60276; United States / NCI NIH HHS / CA / CA-63848; United States / NCI NIH HHS / CA / CA-63849
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Placebos; 0 / Tissue Extracts
  •  go-up   go-down


9. Hutton JL, Baracos VE, Wismer WV: Chemosensory dysfunction is a primary factor in the evolution of declining nutritional status and quality of life in patients with advanced cancer. J Pain Symptom Manage; 2007 Feb;33(2):156-65
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemosensory dysfunction is a primary factor in the evolution of declining nutritional status and quality of life in patients with advanced cancer.
  • Alterations in taste and smell functions have been reported in cancer patients.
  • Although these senses are known to be particularly affected by chemotherapy, many features of chemosensory perception in cancer patients remain obscure.
  • To assess this relationship, self-perceived taste and smell function were evaluated using a validated questionnaire in 66 patients with advanced cancer receiving palliative care (median survival 7.4 months).
  • Severe chemosensory dysfunction is persistent well beyond the window of active therapy in patients with advanced cancer and represents a primary factor relating to malnutrition, wasting, and poor QOL.
  • Further research is required to identify appropriate strategies to alleviate this important group of symptoms, to determine whether intervention will improve QOL, and to match foods and diet to the unique chemosensory profile of advanced cancer patients.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Taste and Smell Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17280921.001).
  • [ISSN] 0885-3924
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


10. Sherman DW, Ye XY, McSherry C, Calabrese M, Parkas V, Gatto M: Spiritual well-being as a dimension of quality of life for patients with advanced cancer and AIDS and their family caregivers: results of a longitudinal study. Am J Hosp Palliat Care; 2005 Sep-Oct;22(5):349-62
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spiritual well-being as a dimension of quality of life for patients with advanced cancer and AIDS and their family caregivers: results of a longitudinal study.
  • Based on a longitudinal, quality-of-life study, this article presents pilot data regarding the spiritual well-being of patients with advanced cancer or AIDS and their family caregivers.


11. Orrevall Y, Tishelman C, Permert J: Home parenteral nutrition: a qualitative interview study of the experiences of advanced cancer patients and their families. Clin Nutr; 2005 Dec;24(6):961-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Home parenteral nutrition: a qualitative interview study of the experiences of advanced cancer patients and their families.
  • BACKGROUND & AIM: The benefit of home parenteral nutrition (HPN) to advanced cancer patients is often debated and an evidence-base for parenteral nutrition (PN) in palliative care is lacking.
  • The aim of this study is to investigate the experiences of HPN from the perspective of advanced cancer patients and their family members.
  • METHODS: Semi-structured interviews were conducted with 13 advanced cancer patients with experience of HPN and 11 family members.
  • Positive statements about HPN were often coupled to the benefits of being enrolled in advanced home care.
  • CONCLUSION: This study indicates that the interviewed cancer patients and their family members experienced physical, social and psychological benefits from HPN treatment.


12. Kelly L, White S, Stone PC: The B12/CRP index as a simple prognostic indicator in patients with advanced cancer: a confirmatory study. Ann Oncol; 2007 Aug;18(8):1395-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The B12/CRP index as a simple prognostic indicator in patients with advanced cancer: a confirmatory study.
  • BACKGROUND: The vitamin B(12)/C-reactive protein Index (BCI) has been proposed as a prognostic indicator in patients with advanced cancer.
  • PATIENTS AND METHODS: Patients with advanced cancer provided a blood specimen for analysis.
  • CONCLUSIONS: An elevated BCI (>40,000) predicts poor survival in patients with advanced cancer.

  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17513884.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 9007-41-4 / C-Reactive Protein; P6YC3EG204 / Vitamin B 12
  •  go-up   go-down


13. Okamoto Y, Tsuneto S, Matsuda Y, Inoue T, Tanimukai H, Tazumi K, Ono Y, Kurokawa N, Uejima E: A retrospective chart review of the antiemetic effectiveness of risperidone in refractory opioid-induced nausea and vomiting in advanced cancer patients. J Pain Symptom Manage; 2007 Aug;34(2):217-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective chart review of the antiemetic effectiveness of risperidone in refractory opioid-induced nausea and vomiting in advanced cancer patients.
  • Nausea and vomiting are distressing symptoms in advanced cancer patients.
  • Among the causes is opioid therapy, the mainstay of cancer pain management.
  • When nausea or other opioid side effects occur, it may hamper pain management and undermine the quality of life of cancer patients.
  • We conducted a retrospective chart review to examine whether risperidone is useful for opioid-induced nausea and vomiting in advanced cancer patients (n=20).
  • This observation suggests that risperidone can be an effective antiemetic drug in the treatment of refractory opioid-induced nausea and vomiting in advanced cancer patients.

  • Genetic Alliance. consumer health - Nausea.
  • Genetic Alliance. consumer health - Vomiting.
  • MedlinePlus Health Information. consumer health - Nausea and Vomiting.
  • Hazardous Substances Data Bank. RISPERIDONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17544249.001).
  • [ISSN] 0885-3924
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Dopamine Antagonists; L6UH7ZF8HC / Risperidone
  •  go-up   go-down


14. Zhang S, Xu G, Liu C, Xiao S, Sun Y, Su X, Cai Y, Li D, Xu B: Clinical study of recombinant adenovirus-p53 (Adp53) combined with hyperthermia in advanced cancer (a report of 15 cases). Int J Hyperthermia; 2005 Nov;21(7):631-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical study of recombinant adenovirus-p53 (Adp53) combined with hyperthermia in advanced cancer (a report of 15 cases).
  • The study was to evaluate the efficacy of the Adp53 combined with hyperthermia on advanced cancer.
  • Fifteen patients with advanced cancer were enrolled in this clinical trial.
  • In conclusion, Adp53 combined with hyperthermia was safe and effective in patients with advanced cancer and p53 gene therapy was potential to thermosensitize in advanced cancer.
  • [MeSH-minor] Adenoviruses, Human / genetics. Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Genes, p53. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / therapy

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304714.001).
  • [ISSN] 0265-6736
  • [Journal-full-title] International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  • [ISO-abbreviation] Int J Hyperthermia
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


15. Mercadante S, Villari P, Ferrera P, David F, Intravaia G: High-dose furosemide and small-volume hypertonic saline solution infusion for the treatment of leg edema in advanced cancer patients. J Pain Symptom Manage; 2009 Mar;37(3):419-23
Hazardous Substances Data Bank. FUROSEMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose furosemide and small-volume hypertonic saline solution infusion for the treatment of leg edema in advanced cancer patients.
  • Peripheral edema is a common feature in populations with advanced cancer, although it is seldom recognized.
  • The aim of this prospective study was to evaluate the efficacy and tolerability of high-dose furosemide and small-volume hypertonic saline solution infusion in reducing leg edema in patients with advanced cancer treated unsuccessfully with diuretics.
  • To be eligible to enter the trial, advanced cancer patients had to have diffuse bilateral leg edema unresponsive to common doses of diuretics.
  • These observations suggest that high-dose furosemide and small-volume saline may be an effective strategy for the treatment of peripheral edema in patients with advanced cancer.

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - Edema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18790601.001).
  • [ISSN] 1873-6513
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diuretics; 0 / Saline Solution, Hypertonic; 7LXU5N7ZO5 / Furosemide
  •  go-up   go-down


16. Nayl B, Durando X, Pomel C, Dubray P, Mouret-Reynier M, Le Bouedec G, Gimbergues P, Chollet P, Dauplat J, Cure H: Six versus nine cycles of paclitaxel-carboplatin as first-line chemotherapy in patients with newly diagnosed epithelial advanced ovarian cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16535

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Six versus nine cycles of paclitaxel-carboplatin as first-line chemotherapy in patients with newly diagnosed epithelial advanced ovarian cancer.
  • : e16535 Background: A multimodality approach with cytoreductive surgery and six courses of paclitaxel-platinum-based chemotherapy is actually the mainstay of treatment of Advanced Ovarian Cancer (AOC).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960781.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Berman DM, Wolchok J, Weber J, Hamid O, O'Day S, Chasalow SD: Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab. J Clin Oncol; 2009 May 20;27(15_suppl):3020

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab.
  • : 3020 Background: Ipilimumab, an anti-CTLA-4 monoclonal antibody, induces durable survival benefits in advanced melanoma pts.
  • Peripheral ALC from routine safety labs were collected from 533 pts with unresectable stage III/IV malignant melanoma treated with ipilimumab 0.3, 3, or 10 mg/kg (recommended dose) in 4 Phase II studies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962073.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Saif MW, Li J, Lamb L, Rosenberg A, Elligers K, Ruta S, Mezes M, Grant N, Liu SH, Chu E, Cheng Y: A phase II study of capecitabine (CAP) plus PHY906 in patients (pts) with advanced pancreatic cancer (APC). J Clin Oncol; 2009 May 20;27(15_suppl):e15508

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of capecitabine (CAP) plus PHY906 in patients (pts) with advanced pancreatic cancer (APC).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962238.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Clive S, Woo MM, Stewart M, Nydam T, Hirawat S, Kagan M: Elucidation of the metabolic and elimination pathways of panobinostat (LBH589) using [<sup>14</sup>C]-panobinostat. J Clin Oncol; 2009 May 20;27(15_suppl):2549

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Four patients with advanced cancer received a single oral 20 mg dose of [<sup>14</sup>C]-PAN (50 μCi).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961858.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Jung G, Knight D, Moadel A, Desai K, Chaudhary I, Gajavelli S, Ghalib MH, Mani S, Goel S: Assessment of quality of life using FACT-G survey in a phase I trial in cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):e20709

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of quality of life using FACT-G survey in a phase I trial in cancer patients.
  • However, there is paucity of evaluation of QoL in patients with advanced cancer participating in Phase I clinical trials.
  • RESULTS: Forty-one of 47 patients with advanced solid tumors who participated in the clinical trial completed FACT-G surveys.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961984.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Goldberg RJ, Jang RW, Leighl NB: A willingness-to-pay study of vascular endothelial growth factor inhibitors among patients with advanced non-small cell lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):6581

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A willingness-to-pay study of vascular endothelial growth factor inhibitors among patients with advanced non-small cell lung cancer.
  • : 6581 Background: Bevacizumab, a recombinant antibody which neutralizes vascular endothelial growth factor (VEGF), has been approved for the treatment of advanced non-small cell lung cancer (NSCLC).
  • Costs of novel anticancer medications such as bevacizumab can be prohibitive for many lung cancer patients.
  • METHODS: Participants attending outpatient lung cancer clinics at a major Canadian cancer center were given information pertaining to the risks and benefits of treatment with bevacizumab and were then asked about their WTP for this agent.
  • RESULTS: 35 advanced NSCLC patients with a median age of 64.5 years and a median income of $40,000-$60,000 CAD consented to participate.
  • (2) patients understand that the government cannot fund all novel cancer therapies;.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963822.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Dong M, Ning Z, Newman MJ, Xu J, Dou G, Cao H, Shi Y, Gingras MA, Lu X, Feng F: Phase I study of chidamide (CS055/HBI-8000), a novel histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas. J Clin Oncol; 2009 May 20;27(15_suppl):3529

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of chidamide (CS055/HBI-8000), a novel histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas.
  • This Phase I study evaluated the safety and tolerability of chidamide in patients (pts) with advanced solid tumors and lymphomas.
  • METHODS: 31 pts with refractory or relapsed advanced solid tumors (22) and lymphomas (9) were enrolled in this study.
  • CONCLUSIONS: Chidamide was well-tolerated in pts with advanced solid tumors and lymphomas in the tested regimens.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961317.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Delgado-Guay MO, Yennurajalingam S, Bruera E: Delirium with severe symptom expression related to hypercalcemia in a patient with advanced cancer: an interdisciplinary approach to treatment. J Pain Symptom Manage; 2008 Oct;36(4):442-9
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delirium with severe symptom expression related to hypercalcemia in a patient with advanced cancer: an interdisciplinary approach to treatment.
  • Delirium is considered to be multifactorial, especially in elderly patients and those with advanced cancer, and can cause significant distress.
  • Hypercalcemia is one of the reversible metabolic causes of delirium in patients with advanced cancer.

  • MedlinePlus Health Information. consumer health - Delirium.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18440772.001).
  • [ISSN] 1873-6513
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Sherman DW, Norman R, McSherry CB: A comparison of death anxiety and quality of life of patients with advanced cancer or AIDS and their family caregivers. J Assoc Nurses AIDS Care; 2010 Mar-Apr;21(2):99-112
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of death anxiety and quality of life of patients with advanced cancer or AIDS and their family caregivers.
  • Based on a sample of 101 patients (63 patients with AIDS and 38 with advanced cancer) and 79 family caregivers (43 AIDS patients' caregivers and 36 cancer patients' caregivers), this study examined the death anxiety of patients with advanced cancer and patients with AIDS and that of their family caregivers and the relationship of death anxiety and quality of life.
  • The results indicated that AIDS patients expressed greater death anxiety than cancer patients, but death anxiety was not different among family caregivers.
  • Both AIDS and cancer patients experienced greater death anxiety than their caregivers.


25. Strasser F, Binswanger J, Cerny T, Kesselring A: Fighting a losing battle: eating-related distress of men with advanced cancer and their female partners. A mixed-methods study. Palliat Med; 2007 Mar;21(2):129-37
MedlinePlus Health Information. consumer health - Stress.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fighting a losing battle: eating-related distress of men with advanced cancer and their female partners. A mixed-methods study.
  • BACKGROUND: Anorexia/cachexia is a frequent complication of advanced cancer with poorly understood psychosocial impact or eating-related distress (ERD) on both patients and family members.
  • To assist palliative care practitioners manage this important psychosocial aspect of care, we aimed to discover and describe elements of ERD, focusing on male patients with advanced cancer and their female partners.
  • CONCLUSION: Anorexia/cachexia of male cancer patients affects the cooking at home, a couple's daily eating routines, and their spousal relationship.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17344261.001).
  • [ISSN] 0269-2163
  • [Journal-full-title] Palliative medicine
  • [ISO-abbreviation] Palliat Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


26. Cherny NI: Evaluation and management of treatment-related diarrhea in patients with advanced cancer: a review. J Pain Symptom Manage; 2008 Oct;36(4):413-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation and management of treatment-related diarrhea in patients with advanced cancer: a review.
  • Diarrhea is a common and significant problem among patients with advanced cancer.
  • The causes of diarrhea among patients with advanced cancer are diverse and some causes of diarrhea require specific therapies.
  • Palliative care clinicians, particularly those dealing with patients receiving ongoing disease-modifying therapies, must be familiar with the common causes of diarrhea among cancer patients and the strategies to evaluate and manage these common and distressing symptoms.

  • Genetic Alliance. consumer health - Diarrhea.
  • MedlinePlus Health Information. consumer health - Diarrhea.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18411014.001).
  • [ISSN] 1873-6513
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidiarrheals
  • [Number-of-references] 80
  •  go-up   go-down


27. Okamura M, Akizuki N, Nakano T, Shimizu K, Ito T, Akechi T, Uchitomi Y: Clinical experience of the use of a pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer. Psychooncology; 2008 Feb;17(2):154-60
Hazardous Substances Data Bank. AMITRIPTYLINE HYDROCHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical experience of the use of a pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer.
  • The objective of this study was to describe the applicability and the dropout of the pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer.
  • Psychiatrists treated major depressive disorder in advanced cancer patients on the basis of the algorithm.
  • [MeSH-minor] Adult. Aged. Alprazolam / therapeutic use. Amitriptyline / therapeutic use. Anxiety Disorders / epidemiology. Anxiety Disorders / prevention & control. Anxiety Disorders / psychology. Central Nervous System Stimulants / therapeutic use. Clomipramine / therapeutic use. Disease Progression. Drug Therapy, Combination. Female. Humans. Male. Methylphenidate / therapeutic use. Middle Aged. Neoplasm Staging. Prognosis. Severity of Illness Index

  • Genetic Alliance. consumer health - Major depressive disorder.
  • MedlinePlus Health Information. consumer health - Antidepressants.
  • Hazardous Substances Data Bank. METHYLPHENIDATE .
  • Hazardous Substances Data Bank. ALPRAZOLAM .
  • Hazardous Substances Data Bank. Clomipramine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17461435.001).
  • [ISSN] 1057-9249
  • [Journal-full-title] Psycho-oncology
  • [ISO-abbreviation] Psychooncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antidepressive Agents; 0 / Central Nervous System Stimulants; 12794-10-4 / Benzodiazepines; 1806D8D52K / Amitriptyline; 207ZZ9QZ49 / Methylphenidate; NUV44L116D / Clomipramine; YU55MQ3IZY / Alprazolam
  •  go-up   go-down


28. Rodriguez CP, Adelstein DJ, Saxton JP, Rybicki LA, Lorenz RR, Wood BG, Scharpf J, Lee WT, Ives DI: Multiagent concurrent chemoradiotherapy (MACCRT) and gefitinib in locoregionally advanced head and neck squamous cell cancer (HNSCC). J Clin Oncol; 2009 May 20;27(15_suppl):6037

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiagent concurrent chemoradiotherapy (MACCRT) and gefitinib in locoregionally advanced head and neck squamous cell cancer (HNSCC).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961912.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Ma CX, Lin L, Gao F, Giuntoli T, Chia YH, Guo Z, McDowell R, Naughton M, Watson M, Ellis M: PIK3CA mutation analysis in recurrent breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):11041

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PIK3CA mutation analysis in recurrent breast cancer.
  • : 11041 Background: Mutations in PIK3CA (encoding p110α catalytic subunit of phosphatidylinositol-3-kinase) are among the most common genetic events identified in breast cancer but the role of these mutations in determining the clinical course of the disease is uncertain.
  • Furthermore the frequency of PIK3CA mutation in metastatic breast cancer samples has not been adequately studied but is an important concern in the design of studies with novel agents designed to inhibit mutant PIK3CA.
  • METHODS: We have established a tumor banking protocol for patients (pts) with metastatic breast cancer.
  • CONCLUSIONS: About one quarter of pts with recurrent/advanced breast cancer carry PIK3CA mutations in samples of recurrent disease, which correlated with positive ER/PR status and a more indolent clinical course.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963981.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Loehr M, Bodoky G, Fölsch U, Märten A, Karrasch M, Lilla C, Meyer I, Osinsky D, Szanto J, Lutz M: Cationic liposomal paclitaxel in combination with gemcitabine in patients with advanced pancreatic cancer: A phase II trial. J Clin Oncol; 2009 May 20;27(15_suppl):4526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cationic liposomal paclitaxel in combination with gemcitabine in patients with advanced pancreatic cancer: A phase II trial.
  • We present safety and efficacy data of a randomized, controlled phase II trial in pancreatic cancer (PC).
  • METHODS: 200 patients with advanced PC were randomized to 1<sup>st</sup> line treatment with weekly gemcitabine (GEM: 1000 mg/m<sup>2</sup>) and twice weekly infusions of EndoTAG-1 (E) at 3 different dose levels (E<sub>low</sub>: 11 mg/m<sup>2</sup>, E<sub>med</sub>: 22 mg/m<sup>2</sup>, E<sub>high</sub>: 44 mg/m<sup>2</sup>) or GEM monotherapy.
  • CONCLUSIONS: This phase II trial indicates a considerable survival benefit for patients with advanced PC receiving EndoTAG-1 in combination with gemcitabine and a favourable safety profile warranting further development of EndoTAG-1 in this indication.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962719.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Awada AH Sr, Dumez H, Wolter P, Hendlisz A, Besse-Hammer T, Piccart M, Uttenreuther-Fischer M, Stopfer P, Taton M, Schöffski P: A phase I dose finding study of the 3-day administration of BIBW 2992, an irreversible dual EGFR/HER-2 inhibitor, in combination with three-weekly docetaxel in patients with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):3556

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I dose finding study of the 3-day administration of BIBW 2992, an irreversible dual EGFR/HER-2 inhibitor, in combination with three-weekly docetaxel in patients with advanced solid tumors.
  • METHODS: Patients (pts) had advanced solid malignancies and received docetaxel 75 mg/m<sup>2</sup> i.v. on Day 1 and oral BIBW 2992 once daily on Days 2-4, in 3-week cycles.
  • Four pts (breast cancer [2], thymoma [1], oesophageal carcinoma [1]) had a PR.
  • One breast cancer pt had a confirmed CR.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961365.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. O'Day S, Weber J, Lebbe C, Maio M, Pehamberger H, Harmankaya K, Siegel J, Hoos A, Humphrey R, Wolchok J: Effect of ipilimumab treatment on 18-month survival: Update of patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials. J Clin Oncol; 2009 May 20;27(15_suppl):9033

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of ipilimumab treatment on 18-month survival: Update of patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials.
  • Updated survival data (≤32.5 months follow-up) from 3 Phase II trials of ipilimumab in pts with mostly pretreated advanced melanoma are reported.
  • CONCLUSIONS: Ipilimumab may result in a long-term survival benefit in pts with advanced melanoma, where 18-month survival rates across 3 Phase II studies range from 34.5% to 39.4% for previously treated pts.
  • These results indicate that more than 1/3 of ipilimumab-treated pts with advanced melanoma experience a long-term survival benefit, including some pts characterized as PD by mWHO.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962088.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Agarwala AK, Hanna N, McCollum A, Bechar N, DiMaio M, Yu M, Tong Y, Becerra CR, Choy H: Preoperative cetuximab and radiation (XRT) for patients (pts) with surgically resectable esophageal and gastroesophageal junction (GEJ) carcinomas: A pilot study from the Hoosier Oncology Group and the University of Texas Southwestern. J Clin Oncol; 2009 May 20;27(15_suppl):4557

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cetuximab, when combined with XRT is effective treatment for locally advanced cancers of the head and neck.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963028.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Correa-Velez I, Clavarino A, Eastwood H: Surviving, relieving, repairing, and boosting up: reasons for using complementary/alternative medicine among patients with advanced cancer: a thematic analysis. J Palliat Med; 2005 Oct;8(5):953-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surviving, relieving, repairing, and boosting up: reasons for using complementary/alternative medicine among patients with advanced cancer: a thematic analysis.
  • BACKGROUND: Patients with advanced cancer commonly use complementary and alternative medicine (CAM), however, little research has been undertaken on their reasons for doing so.
  • OBJECTIVES: This study sought to identify in detail the reasons for using CAM among patients with advanced cancer.
  • SETTING/SUBJECTS: Interviews conducted with 39 patients who were participating in a longitudinal study exploring the levels of palliative care received by patients with cancer in Brisbane, Australia.
  • All participants were receiving or had received conventional cancer treatments.
  • RESULTS: Most participants self-treated with CAM and perceived CAM modalities as complementary rather than alternative to conventional cancer treatments.
  • Within this context, this group of people used CAM to prolong their survival, palliate their symptoms or alleviate the side effects of conventional cancer treatments, detoxify their bodies, boost immunity and enhance their overall quality of life.
  • CONCLUSION: When facing an incurable life-threatening illness such as advanced cancer, the decision to use CAM is a pragmatic one.
  • Screening for physical, emotional, and spiritual discomfort associated not only with the disease but with some of the cancer treatments needs to be given a prominent place in the clinical encounter.
  • Patients with cancer want to know more about how to maintain or improve their quality of life during and after surgery, radiation, or chemotherapy.


35. Poon D, Lee HH, Chan LL, Yap R, Koo WH: An exploratory analysis of comprehensive geriatric assessment results and overall survival in 233 consecutive elderly cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):9504

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An exploratory analysis of comprehensive geriatric assessment results and overall survival in 233 consecutive elderly cancer patients.
  • : 9504 Background: Performance status (PS) is the main clinical parameter used by most oncologists to assess the ability of elderly cancer patients to tolerate chemotherapy and estimate prognosis.
  • The results of comprehensive geriatric assessment (CGA) for elderly cancer patients were analyzed to investigate the impact of each CGA functional, physical, cognitive, and affective domain on overall survival in relation to performance status.
  • METHODS: CGA was used for 233 consecutive elderly cancer patients aged 70 and above.
  • Cancer type and stage were also analyzed.
  • Univariate and multivariate analyses were done to assess impact of ECOG status, presence of geriatric syndrome, stage of disease and cancer type on overall survival.
  • RESULTS: All 233 patients were included in the analysis, median age 77 (70 - 93), all had solid tumors and predominant tumors comprising 79% of diagnoses were colorectal, lung and breast, 50% had advanced metastatic disease.
  • ECOG grades 2,3,4 (HR 0.28, 95% CI 0.14 - 0.55), dependent IADL status (HR 0.30, 95% CI 0.11 - 0.83), presence of geriatric syndrome (HR 0.42 95% CI 0.26 - 0.69), poor cognition (HR 0.53 95% CI 0.36 - 0.77), or advanced disease (HR 0.30 95% CI 0.14 - 0.65) was associated with inferior overall survival in univariate analysis.
  • Only poor ECOG status, presence of a geriatric syndrome and advanced disease predicted adversely for overall survival in multivariate analysis.
  • CONCLUSIONS: Utility of CGA will improve the assessment of the elderly cancer patient.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964457.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Bissonnette JP, Purdie T, Higgins J, Li W, Bezjak A: Poster - Thurs Eve-22: Image guided radiation therapy for lung cancer. Med Phys; 2008 Jul;35(7Part2):3405

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poster - Thurs Eve-22: Image guided radiation therapy for lung cancer.
  • IGRT was also used to assess the initial and residual errors for lung cancer patients treated conventionally with (14 pts; 584 CBCT) and without (25 pts; 1032 CBCT) a remote-controlled treatment couch.
  • For conventional lung cancer patients, Σ and σ ranged between 1.4 and 3.8 mm, and IGRT raises the proportion of patients within ± 3 mm from 27% to 67%, with the remote-controlled couch further improving this proportion to 84%.
  • This new paradigm has been transported to patients with locally-advanced lung cancer, with similar accuracy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 American Association of Physicists in Medicine.
  • (PMID = 28512797.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cancer / Computed tomography / Cone beam computed tomography / Dosimetry / Image guided radiation therapy / Lungs / Medical imaging / Radiation therapy / Therapeutics
  •  go-up   go-down


37. Stockler MR, O'Connell R, Nowak AK, Goldstein D, Turner J, Wilcken NR, Wyld D, Abdi EA, Glasgow A, Beale PJ, Jefford M, Dhillon H, Heritier S, Carter C, Hickie IB, Simes RJ, Zoloft's Effects on Symptoms and survival Time Trial Group: Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. Lancet Oncol; 2007 Jul;8(7):603-12
Hazardous Substances Data Bank. SERTRALINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial.
  • BACKGROUND: Depression, anxiety, fatigue, and impaired wellbeing are common, important, and closely related in advanced cancer.
  • We aimed to identify the effects of an established antidepressant on these symptoms and survival in patients with advanced cancer who did not have major depression as assessed by clinicians.
  • METHODS: Between July, 2001, and February, 2006, 189 patients with advanced cancer were randomly assigned sertraline 50 mg (n=95), or placebo (n=94), once per day.
  • The primary outcome was depression as assessed by the Centre for Epidemiologic Studies Depression scale (CES-D); the main secondary outcomes were: anxiety as assessed by Hospital Anxiety and Depression Scales (HADS-A); overall quality of life and fatigue as assessed by Functional Assessment of Cancer Therapy General and Fatigue scales (FACT-G and FACT-F, respectively); and clinicians' ratings of quality of life by use of Spizter's Quality of Life Index (SQLI).
  • INTERPRETATION: Sertraline did not improve symptoms, wellbeing, or survival in patients with advanced cancer who do not have major depression, and should be reserved for those with a proven indication.

  • Genetic Alliance. consumer health - Depression.
  • Genetic Alliance. consumer health - Major depressive disorder.
  • MedlinePlus Health Information. consumer health - Antidepressants.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2007 Jul;8(7):567-8 [17613418.001]
  • [ErratumIn] Lancet Oncol. 2007 Jul 8;8(7):574
  • (PMID = 17548243.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN72466475
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antidepressive Agents; 0 / Placebos; QUC7NX6WMB / Sertraline
  •  go-up   go-down


38. Sherman DW, Ye XY, Beyer McSherry C, Parkas V, Calabrese M, Gatto M: Symptom assessment of patients with advanced cancer and AIDS and their family caregivers: the results of a quality-of-life pilot study. Am J Hosp Palliat Care; 2007 Oct-Nov;24(5):350-65
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Symptom assessment of patients with advanced cancer and AIDS and their family caregivers: the results of a quality-of-life pilot study.
  • This longitudinal pilot study examined differences in demographic characteristics of 101 patients with advanced illness (cancer, AIDS) and 81 Family caregivers, evaluated the reliability of the Memorial Symptom Assessment Scale for these patients and their family caregivers; obtained preliminary data regarding similarities or differences in the symptom experience oF these patients and their family caregivers and changes in symptoms over time; and identified demographic variables that may be potential covariates related to the symptom experience.
  • All demographic variables were significantly different for patients with advanced cancer and AIDS, and their symptom experience is similar only with regard to psychologic symptoms; however, based on the Memorial Symptom Assessment Scale, cancer and AIDS patients and their family caregivers have similar symptom experiences, indicating the need for palliative care for both patients and family.


39. Strasser F, Müller-Käser I, Dietrich D: Evaluating cognitive, emotional, and physical fatigue domains in daily practice by single-item questions in patients with advanced cancer: a cross-sectional pragmatic study. J Pain Symptom Manage; 2009 Oct;38(4):505-14
MedlinePlus Health Information. consumer health - Fatigue.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluating cognitive, emotional, and physical fatigue domains in daily practice by single-item questions in patients with advanced cancer: a cross-sectional pragmatic study.
  • To assess cancer-related fatigue (CRF), multidimensional questionnaires are required.
  • Sixty-one fatigued patients with advanced cancer completed SIF assessments (visual analog scales for global fatigue and for fatigue in the cognitive, emotional, and physical domains, respectively), and the Brief Fatigue Inventory (BFI), the Fatigue Assessment Questionnaire (FAQ), the Hospital Anxiety and Depression Scale (HADS), and the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life-C30 (QLQ-C30).
  • These data suggest that three simple SIF questions permit rapid assessment of the physical and cognitive and probably the emotional domains of CRF in patients with advanced cancer.

  • MedlinePlus Health Information. consumer health - Anxiety.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19822275.001).
  • [ISSN] 1873-6513
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Maltoni M, Caraceni A, Brunelli C, Broeckaert B, Christakis N, Eychmueller S, Glare P, Nabal M, Viganò A, Larkin P, De Conno F, Hanks G, Kaasa S, Steering Committee of the European Association for Palliative Care: Prognostic factors in advanced cancer patients: evidence-based clinical recommendations--a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol; 2005 Sep 1;23(25):6240-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in advanced cancer patients: evidence-based clinical recommendations--a study by the Steering Committee of the European Association for Palliative Care.
  • PURPOSE: To offer evidence-based clinical recommendations concerning prognosis in advanced cancer patients.
  • Only studies on patients with advanced cancer and survival < or = 90 days were included.
  • Recommendations on the use of other prognostic factors, such as performance status, symptoms associated with cancer anorexia-cachexia syndrome (weight loss, anorexia, dysphagia, and xerostomia), dyspnea, delirium, and some biologic factors (leukocytosis, lymphocytopenia, and C-reactive protein), reached level B.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16135490.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  • [Number-of-references] 80
  •  go-up   go-down


41. Shroff RT, Javle MM, Dong X, Kumar VS, Krishnan S, Wolff RA, Abbruzzese JL, Li D: The prognostic value of polymorphisms in the insulin-like growth factor receptor (IGFR) pathway in patients with locally advanced pancreatic cancer (LAPC). J Clin Oncol; 2009 May 20;27(15_suppl):4500

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic value of polymorphisms in the insulin-like growth factor receptor (IGFR) pathway in patients with locally advanced pancreatic cancer (LAPC).
  • : 4500 Background: The IGFR pathway is activated in pancreatic cancer and may result in aggressive disease course.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962692.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Lee MS, Yang SH, Lee KK, Moon SR: Effects of Qi therapy (external Qigong) on symptoms of advanced cancer: a single case study. Eur J Cancer Care (Engl); 2005 Dec;14(5):457-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of Qi therapy (external Qigong) on symptoms of advanced cancer: a single case study.
  • The aim of this study was to examine the effectiveness of Qi therapy (external Qigong) in the management of symptoms of advanced cancer in a man.
  • We used a single case study design to evaluate the effectiveness of Qi therapy (external Qigong) in a 35-year-old man with advanced cancer (Stage IV) involving metastases in the stomach, lung and bone (Karnofsky performance scale: KPS, 40: requires special care and assistance, disabled).
  • A visual analogue scale (VAS) was used to assess the patient's self-reported symptoms of cancer over the intervention and follow-up periods.

  • MedlinePlus Health Information. consumer health - Fatigue.
  • MedlinePlus Health Information. consumer health - Insomnia.
  • MedlinePlus Health Information. consumer health - Nausea and Vomiting.
  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16274468.001).
  • [ISSN] 0961-5423
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


43. Drevs J, Medinger M, Mross K, Fuxius S, Hennig J, Buechert M, Thomas A, Unger C, Chen BL, Lebwohl D, Laurent D: A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer. Anticancer Res; 2010 Jun;30(6):2335-9
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer.
  • Seventy-one patients with advanced cancer were enrolled to receive once daily dosing.
  • CONCLUSION: An MTD was not reached in this study but, based on these data and findings from other studies, 1200 mg was found to be the optimum dose of PTK/ZK for patients with advanced cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20651389.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Phthalazines; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2; 5DX9U76296 / vatalanib
  •  go-up   go-down


44. Yennurajalingam S, Dev R, Walker PW, Reddy SK, Bruera E: Challenges associated with spinal opioid therapy for pain in patients with advanced cancer: a report of three cases. J Pain Symptom Manage; 2010 May;39(5):930-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Challenges associated with spinal opioid therapy for pain in patients with advanced cancer: a report of three cases.
  • Intraspinal opioid therapy has been increasingly used for the management of cancer pain refractory to traditional treatment.
  • However, this approach may present challenges in patients with advanced cancer.
  • Three cases are presented that highlight the challenges associated with using neuraxial analgesia to manage cancer pain that was felt to be "refractory" to conventional treatment.

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20471553.001).
  • [ISSN] 1873-6513
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid
  •  go-up   go-down


45. Pennington K, Guarino MJ, Serafini AN, Rocha-Lima C, Suppiah K, Schneider CJ, Gold DV, Sharkey RM, Wegener WA, Goldenberg DM: Multicenter study of radiosensitizing gemcitabine combined with fractionated radioimmunotherapy for repeated treatment cycles in advanced pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4620

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter study of radiosensitizing gemcitabine combined with fractionated radioimmunotherapy for repeated treatment cycles in advanced pancreatic cancer.
  • : 4620 Background: In a phase I study, a single dose of <sup>90</sup>Y-labeled anti-mucin humanized antibody, hPAM4 (<sup>90</sup>Y-hPAM4), led to several transient reductions or stabilization of lesions in advanced pancreatic cancer, with bone marrow toxicity limiting the maximum tolerated dose to 20 mCi/m<sup>2</sup>.
  • METHODS: Patients (pts) with previously untreated, locally advanced or metastatic, pancreatic cancer were treated in 4-week cycles (200 mg/m<sup>2</sup> gemcitabine once-weekly; <sup>111</sup>In-hPAM4 the 1<sup>st</sup> wk for imaging, biodistribution, and dosimetry; <sup>90</sup>Y-hPAM4 once-weekly the last 3 wks), which could be repeated in the absence of progression or unacceptable toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964221.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Ishikawa H, Saeki T, Otani T, Suzuki T, Shimozuma K, Nishino H, Fukuda S, Morimoto K: Aged garlic extract prevents a decline of NK cell number and activity in patients with advanced cancer. J Nutr; 2006 Mar;136(3 Suppl):816S-820S
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aged garlic extract prevents a decline of NK cell number and activity in patients with advanced cancer.
  • Advanced-cancer patients decline in immune functions and quality of life (QOL).
  • The study's subjects were patients with inoperable colorectal, liver, or pancreatic cancer.
  • The primary endpoint was a QOL questionnaire based on the Functional Assessment of Cancer Therapy (FACT).
  • They consisted of 42 patients with liver cancer (84%), 7 patients with pancreatic cancer (14%), and 1 patient with colon cancer (2%).
  • The study showed that administering AGE to patients with advanced cancer of the digestive system improved NK cell activity, but caused no improvement in QOL.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16484572.001).
  • [ISSN] 0022-3166
  • [Journal-full-title] The Journal of nutrition
  • [ISO-abbreviation] J. Nutr.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Placebos; 0 / Plant Extracts
  •  go-up   go-down


47. Porzio G, Aielli F, Verna L, Aloisi P, Galletti B, Ficorella C: Gabapentin in the treatment of hiccups in patients with advanced cancer: a 5-year experience. Clin Neuropharmacol; 2010 Jul;33(4):179-80
Hazardous Substances Data Bank. GABAPENTIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gabapentin in the treatment of hiccups in patients with advanced cancer: a 5-year experience.
  • AIM: To evaluate safety and efficacy of gabapentin in the treatment of severe chronic hiccups in patients with advanced cancer.
  • CONCLUSION: The results of the study allow suggesting gabapentin at least as a promising drug in the treatment of severe chronic hiccups in advanced cancer patients.

  • MedlinePlus Health Information. consumer health - Hiccups.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20414106.001).
  • [ISSN] 1537-162X
  • [Journal-full-title] Clinical neuropharmacology
  • [ISO-abbreviation] Clin Neuropharmacol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amines; 0 / Calcium Channel Blockers; 0 / Cyclohexanecarboxylic Acids; 56-12-2 / gamma-Aminobutyric Acid; 6CW7F3G59X / gabapentin
  •  go-up   go-down


48. Groen H, Hochstenbag MM, van Putten JW, Vincent A, Dalesio O, Biesma B, Smit HJ, Termeer A, van den Borne BE, Schramel FM: A randomized placebo-controlled phase III study of docetaxel/carboplatin with celecoxib in patients (pts) with advanced non-small cell lung cancer (NSCLC): The NVALT-4 study. J Clin Oncol; 2009 May 20;27(15_suppl):8005

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized placebo-controlled phase III study of docetaxel/carboplatin with celecoxib in patients (pts) with advanced non-small cell lung cancer (NSCLC): The NVALT-4 study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962783.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Pignata S, Scambia G, Savarese A, Sorio R, Breda E, Ferrandina G, Gebbia V, Musso P, Gallo C, Perrone F: Carboplatin plus paclitaxel versus carboplatin plus stealth liposomal doxorubicin in patients with advanced ovarian cancer (AOC): Final results of the MITO-2 randomized multicenter trial. J Clin Oncol; 2009 May 20;27(15_suppl):LBA5508

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carboplatin plus paclitaxel versus carboplatin plus stealth liposomal doxorubicin in patients with advanced ovarian cancer (AOC): Final results of the MITO-2 randomized multicenter trial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962270.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Wu JC, Hakama M, Anttila A, Yen AM, Malila N, Sarkeala T, Auvinen A, Chiu SY, Chen HH: Estimation of natural history parameters of breast cancer based on non-randomized organized screening data: subsidiary analysis of effects of inter-screening interval, sensitivity, and attendance rate on reduction of advanced cancer. Breast Cancer Res Treat; 2010 Jul;122(2):553-66
MedlinePlus Health Information. consumer health - Mammography.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estimation of natural history parameters of breast cancer based on non-randomized organized screening data: subsidiary analysis of effects of inter-screening interval, sensitivity, and attendance rate on reduction of advanced cancer.
  • Estimating the natural history parameters of breast cancer not only elucidates the disease progression but also make contributions to assessing the impact of inter-screening interval, sensitivity, and attendance rate on reducing advanced breast cancer.
  • Computer simulation was implemented to examine the effect of inter-screening interval, sensitivity, and attendance rate on reducing advanced breast cancers.
  • In three-state model, the MST was 2.02 years, and the sensitivity for detecting preclinical breast cancer was 84.83%.
  • Annual, biennial, and triennial screening programs can reduce 53, 37, and 28% of advanced cancer.
  • We demonstrated how to estimate the natural history parameters using a service screening program and applied these parameters to assess the impact of inter-screening interval, sensitivity, and attendance rate on reducing advanced cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20054645.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


51. Chvetzoff G, Perol D, Devaux Y, Lancry L, Rebattu P, Magnet M, Dubost E, Bertrand M, Garcon C, Thevenet G, Gobet S, Arbiol E, Saltel P: [Prospective study on the quality of care and quality of life in advanced cancer patients treated at home or in hospital: intermediate analysis of the Trapado study]. Bull Cancer; 2006 Feb;93(2):213-21
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prospective study on the quality of care and quality of life in advanced cancer patients treated at home or in hospital: intermediate analysis of the Trapado study].
  • The preferences of advanced cancer patients and the impact of cancer management on relatives remain partly unknown.
  • We present the preliminary results of a prospective study evaluating quality of care (QC), quality of life (QoL) and family impact (FI) in advanced cancer patients treated at home or in hospital, depending on their own choice.

  • MedlinePlus Health Information. consumer health - Home Care Services.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16517418.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


52. O'Hara RE, Hull JG, Lyons KD, Bakitas M, Hegel MT, Li Z, Ahles TA: Impact on caregiver burden of a patient-focused palliative care intervention for patients with advanced cancer. Palliat Support Care; 2010 Dec;8(4):395-404
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact on caregiver burden of a patient-focused palliative care intervention for patients with advanced cancer.
  • OBJECTIVE: Caregivers of patients with advanced cancer experience physical and emotional strain that can raise their own risk for morbidity and mortality.
  • METHOD: Caregivers of patients with advanced cancer from the parent study completed a caregiver burden scale and patients completed quality of life, symptom intensity, and depressed mood measures.

  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • MedlinePlus Health Information. consumer health - Caregivers.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Stress.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 1999 Dec 15;282(23):2215-9 [10605972.001]
  • [Cites] JAMA. 2009 Aug 19;302(7):741-9 [19690306.001]
  • [Cites] Psychol Aging. 2000 Jun;15(2):259-71 [10879581.001]
  • [Cites] Am J Nurs. 2000 Dec;100(12):26-31; quiz 32 [11202781.001]
  • [Cites] Oncol Nurs Forum. 2001 Aug;28(7):1149-57 [11517848.001]
  • [Cites] J Pain Symptom Manage. 2001 Sep;22(3):752-8 [11532588.001]
  • [Cites] Health Psychol. 2001 Nov;20(6):452-7 [11714188.001]
  • [Cites] Gerontologist. 2002 Jun;42(3):356-72 [12040138.001]
  • [Cites] Soc Sci Med. 2003 Jan;56(1):95-109 [12435554.001]
  • [Cites] Palliat Med. 2003 Jan;17(1):63-74 [12597468.001]
  • [Cites] J Gerontol B Psychol Sci Soc Sci. 2003 Mar;58(2):P112-28 [12646594.001]
  • [Cites] Psychol Aging. 2003 Jun;18(2):250-67 [12825775.001]
  • [Cites] Support Care Cancer. 2003 Oct;11(10):638-43 [12905058.001]
  • [Cites] Palliat Med. 2004 Mar;18(2):108-20 [15046407.001]
  • [Cites] J Palliat Care. 1991 Summer;7(2):6-9 [1714502.001]
  • [Cites] Soc Sci Med. 1995 Feb;40(4):517-28 [7725125.001]
  • [Cites] Cancer Treat Rev. 1996 Jan;22 Suppl A:3-12 [8625346.001]
  • [Cites] J Pain Symptom Manage. 1997 Mar;13(3):138-47 [9114632.001]
  • [Cites] Nurs Res. 1998 Jan-Feb;47(1):2-10 [9478178.001]
  • [Cites] Psychooncology. 1998 Jan-Feb;7(1):3-13 [9516646.001]
  • [Cites] Image J Nurs Sch. 1999;31(2):115-20 [10380385.001]
  • [Cites] Oncol Nurs Forum. 2004 Nov;31(6):1105-17 [15547633.001]
  • [Cites] J Pain Symptom Manage. 2005 Aug;30(2):112-22 [16125026.001]
  • [Cites] J Pain Symptom Manage. 2005 Oct;30(4):329-41 [16256897.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):214-22 [16329131.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):719-30 [16481639.001]
  • [Cites] Am J Hosp Palliat Care. 2006 Jun-Jul;23(3):185-91 [17060277.001]
  • [Cites] Arch Intern Med. 2007 Jan 8;167(1):40-6 [17210876.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4829-34 [17947732.001]
  • [Cites] J Pain Symptom Manage. 2007 Nov;34(5):539-46 [17616333.001]
  • [Cites] J Psychosom Res. 2007 Dec;63(6):617-23 [18061752.001]
  • [Cites] Ann Intern Med. 2008 Jan 15;148(2):147-59 [18195339.001]
  • [Cites] Psychol Bull. 2008 Jan;134(1):1-30 [18193993.001]
  • [Cites] Clin J Oncol Nurs. 2008 Jun;12(3):507-16 [18515250.001]
  • [Cites] Am J Public Health. 2008 Nov;98(11):2092-8 [18511733.001]
  • [Cites] J Clin Oncol. 2008 Dec 20;26(36):5890-5 [19029423.001]
  • [Cites] J Pain Symptom Manage. 2009 Jan;37(1):23-32 [18504093.001]
  • [Cites] Palliat Support Care. 2009 Mar;7(1):75-86 [19619377.001]
  • [Cites] Cancer Treat Res. 1999;100:203-16 [10645504.001]
  • (PMID = 20875202.001).
  • [ISSN] 1478-9523
  • [Journal-full-title] Palliative & supportive care
  • [ISO-abbreviation] Palliat Support Care
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA101704; United States / NCI NIH HHS / CA / CA101704-03; United States / NCI NIH HHS / CA / CA101704-02; United States / NCI NIH HHS / CA / P30 CA023108; United States / NCI NIH HHS / CA / R01 CA101704-01; United States / NCI NIH HHS / CA / R01 CA101704-02; United States / NCI NIH HHS / CA / R01 CA101704-03; United States / NCI NIH HHS / CA / CA101704-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS277192; NLM/ PMC3063059
  •  go-up   go-down


53. Homma A, Oridate N, Suzuki F, Taki S, Asano T, Yoshida D, Onimaru R, Nishioka T, Shirato H, Fukuda S: Superselective high-dose cisplatin infusion with concomitant radiotherapy in patients with advanced cancer of the nasal cavity and paranasal sinuses: a single institution experience. Cancer; 2009 Oct 15;115(20):4705-14
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superselective high-dose cisplatin infusion with concomitant radiotherapy in patients with advanced cancer of the nasal cavity and paranasal sinuses: a single institution experience.
  • BACKGROUND: The current study aimed to evaluate the efficacy of superselective high-dose cisplatin infusion with concomitant radiotherapy (RADPLAT) for previously untreated patients with advanced cancer of the nasal cavity and paranasal sinuses.
  • CONCLUSIONS: Although a single institution experience, the results of the current study suggest that RADPLAT can cure the majority of patients with advanced cancer of the nasal cavity and paranasal sinuses, as well as preserve organs.
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / adverse effects. Disease Progression. Female. Humans. Infusions, Intra-Arterial. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Analysis. Thiosulfates / administration & dosage

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 American Cancer Society.
  • (PMID = 19634162.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Thiosulfates; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


54. Brown ER, Charles KA, Hoare SA, Rye RL, Jodrell DI, Aird RE, Vora R, Prabhakar U, Nakada M, Corringham RE, DeWitte M, Sturgeon C, Propper D, Balkwill FR, Smyth JF: A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann Oncol; 2008 Jul;19(7):1340-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer.
  • Infliximab, an anti-TNF-alpha monoclonal antibody was investigated in this trial of patients with advanced cancer.
  • The primary objectives were to determine the safety profile and biological response of infliximab in a cancer population.
  • Post-treatment samples were measured for changes in plasma and serum TNF-alpha, CCL2, IL-6 and C-reactive protein (CRP).
  • At both doses of infliximab, neutralisation of serum TNF-alpha was observed after 1 h while plasma CCL2, IL-6 and serum CRP were decreased 24 and 48 h following infliximab administration.
  • CONCLUSIONS: Infliximab treatment was safe and well tolerated in patients with advanced cancer.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Infliximab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18325912.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0501974
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / CCL2 protein, human; 0 / Chemokine CCL2; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha; 9007-41-4 / C-Reactive Protein; B72HH48FLU / Infliximab
  •  go-up   go-down


55. Dennie T, Alberti D, Oliver K, LoConte N, Mulkerin D, Wilding G, Holen K, Fleming R, Bowen C, O'Neill V: A phase I study of capecitabine, oxaliplatin (CapOx), and lapatinib (L) in metastatic or advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):2579

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of capecitabine, oxaliplatin (CapOx), and lapatinib (L) in metastatic or advanced solid tumors.
  • : 2579 Background: CapOx is a standard treatment for patients (pts) with metastatic colorectal cancer (mCRC) and has been shown to be equivalent to FOLFOX in a phase III study.
  • METHODS: Pts eligible for treatment included those with advanced or metastatic cancers, ECOG PS 2 or less, adequate renal and liver function, and ≤ 3 prior chemotherapy regimens.
  • One pt had breast cancer and the remainder had non- colorectal GI malignancies (esophagus, hepatobiliary, and pancreas).
  • One pt with pancreatic cancer had a confirmed partial response (PR) to treatment, and 3 others had stable disease for > 90 days.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961891.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Oh S, Kim S, Kwon H, Kim H, Hwang I, Kang J, Lee S, Lee J, Kang W: Leptomeningeal carcinomatosis of gastric cancer: Multicenter retrospective analysis of 54 cases. J Clin Oncol; 2009 May 20;27(15_suppl):e15658

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptomeningeal carcinomatosis of gastric cancer: Multicenter retrospective analysis of 54 cases.
  • : e15658 Background: Leptomeningeal carcinomatosis occurs in approximately 5% of patients with cancer.
  • The most common cancers involving the leptomeninges are breast and lung cancer.
  • The majority of patients had advanced disease at the initial diagnosis of gastric cancer.
  • The clinical or pathologic TNM stages of the primary gastric cancer were IV in 38 patients (70%).
  • Clinically, initial advanced stage was predictive value of poor prognosis (P=0.009).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962774.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Schellens JH, Leijen S, Shapiro GI, Pavlick AC, Tibes R, O'Day SJ, Demuth T, Viscusi J, Xu Y, Oza AM: A phase I and pharmacological study of MK-1775, a Wee1 tyrosine kinase inhibitor, in both monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):3510

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I and pharmacological study of MK-1775, a Wee1 tyrosine kinase inhibitor, in both monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.
  • G2 checkpoint abrogation may therefore sensitize p53 deficient tumor cells to anti-cancer agents.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961310.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Melosky B: Shifting the paradigm for maintenance therapy in advanced non-small-cell lung cancer. Lung Cancer (Auckl); 2010;1:53-62

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shifting the paradigm for maintenance therapy in advanced non-small-cell lung cancer.
  • The standard of care in metastatic non-small-cell lung cancer (NSCLC) is to treat patients with a platinum doublet for 4 to 6 cycles and to offer second-line therapy upon progression.
  • In this article a concise recent review of data related to the role of maintenance therapy in patients with advanced NSCLC is provided, complementing previous information in the field.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):777-84 [14990632.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5892-9 [16043829.001]
  • [Cites] J Clin Oncol. 2008 Jul 20;26(21):3543-51 [18506025.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1545-52 [17442998.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):330-53 [14691125.001]
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):3277-83 [19470938.001]
  • [Cites] Lancet. 2008 Nov 22;372(9652):1809-18 [19027483.001]
  • [Cites] Lung Cancer. 2006 May;52(2):155-63 [16569462.001]
  • [Cites] J Natl Cancer Inst. 2005 Apr 6;97(7):499-506 [15812075.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1589-97 [15117980.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2095-103 [10811675.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):785-94 [14990633.001]
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):591-8 [19075278.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):92-8 [11784875.001]
  • [Cites] J Clin Oncol. 2010 Feb 20;28(6):918-27 [20100958.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1227-34 [19188680.001]
  • [Cites] Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37 [16257339.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):123-32 [16014882.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] Lancet. 2009 Oct 24;374(9699):1432-40 [19767093.001]
  • (PMID = 28210106.001).
  • [Journal-full-title] Lung Cancer (Auckland, N.Z.)
  • [ISO-abbreviation] Lung Cancer (Auckl)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Keywords] NOTNLM ; advanced non-small-cell lung cancer / erlotinib / maintenance therapy / pemetrexed
  •  go-up   go-down


59. Plummer R, Hayward L, Lorigan P, Soriano V, Moiseyenko V, Szyldergemajn S, Prados R, Smyth J, Calvert H: Plitidepsin alone or with dacarbazine (DTIC) as first-line treatment for advanced unresectable melanoma (AUM). J Clin Oncol; 2009 May 20;27(15_suppl):9059

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plitidepsin alone or with dacarbazine (DTIC) as first-line treatment for advanced unresectable melanoma (AUM).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962154.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Miller JJ, Frost MH, Rummans TA, Huschka M, Atherton P, Brown P, Gamble G, Richardson J, Hanson J, Sloan JA, Clark MM: Role of a medical social worker in improving quality of life for patients with advanced cancer with a structured multidisciplinary intervention. J Psychosoc Oncol; 2007;25(4):105-19
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of a medical social worker in improving quality of life for patients with advanced cancer with a structured multidisciplinary intervention.
  • <i> BACKGROUND: </i> Patients with advanced cancer face multiple challenges to their quality of life (QOL).
  • The goal of this study was to investigate the impact of participation in a multidisciplinary intervention, including a social service component, on improving the QOL of patients with advanced cancer undergoing radiation therapy.
  • <i> DESIGN: </i> A total of 115 participants with newly diagnosed advanced stage cancer, who were receiving radiation therapy, were randomly assigned to either participate in an 8-session structured multidisciplinary intervention or to receive standard care.
  • <i> CONCLUSIONS: </i> A social work component within a structured multidisciplinary intervention results in significant advantages in the social domain of QOL, and contributes to clinically meaningful improvements in the overall QOL for patients with advanced cancer undergoing active medical treatment.
  • Numerous studies have documented the financial burdens and social changes that may occur with the diagnosis of cancer.
  • [MeSH-major] Health Services / standards. Interdisciplinary Communication. Neoplasm Staging. Neoplasms. Patient Care Team. Quality of Life / psychology. Social Work

  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18032268.001).
  • [ISSN] 0734-7332
  • [Journal-full-title] Journal of psychosocial oncology
  • [ISO-abbreviation] J Psychosoc Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


61. Currow DC, Plummer JL, Cooney NJ, Gorman D, Glare PA: A randomized, double-blind, multi-site, crossover, placebo-controlled equivalence study of morning versus evening once-daily sustained-release morphine sulfate in people with pain from advanced cancer. J Pain Symptom Manage; 2007 Jul;34(1):17-23
Hazardous Substances Data Bank. MORPHINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized, double-blind, multi-site, crossover, placebo-controlled equivalence study of morning versus evening once-daily sustained-release morphine sulfate in people with pain from advanced cancer.
  • The study recruited 45 people with opioid-responsive pain on stable doses of analgesics and advanced cancer from five regional palliative care programs in Australia.
  • This study suggests that any difference between morning and evening dosing of once-daily sustained-release morphine in people with significant opioid-responsive pain and advanced cancer is small and unlikely to be clinically significant for most people.

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17601560.001).
  • [ISSN] 0885-3924
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Delayed-Action Preparations; 0 / Placebos; 76I7G6D29C / Morphine
  •  go-up   go-down


62. Yennurajalingam S, Palmer JL, Zhang T, Poulter V, Bruera E: Association between fatigue and other cancer-related symptoms in patients with advanced cancer. Support Care Cancer; 2008 Oct;16(10):1125-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between fatigue and other cancer-related symptoms in patients with advanced cancer.
  • GOALS OF WORK: Although fatigue is the chronic symptom most commonly experienced by patients with advanced cancer, little research has been done on the associations and correlates of fatigue in this population.
  • The aim of this study was, therefore, to determine whether fatigue scores, as measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), are associated with age, gender, type of cancer diagnosed, pain, and other cancer-related symptoms measured using the Edmonton Symptom Assessment Scale (ESAS).
  • MATERIALS AND METHODS: We retrospectively reviewed the FACIT-F (when a higher score denotes lower fatigue) and ESAS (when a lower fatigue score denotes lower fatigue intensity) scores of 268 patients with advanced cancer who had been previously enrolled in clinical trials of therapies for fatigue.
  • RESULTS: We found no univariate association between fatigue score and gender, ethnicity (p = 0.31), or type of cancer diagnosed.

  • MedlinePlus Health Information. consumer health - Fatigue.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Aug 10;25(23):3475-81 [17687152.001]
  • [Cites] Palliat Med. 2008 Jan;22(1):13-32 [18216074.001]
  • [Cites] Crit Rev Oncol Hematol. 2003 Sep;47(3):273-9 [12962901.001]
  • [Cites] Support Care Cancer. 1996 Mar;4(2):82-96 [8673356.001]
  • [Cites] J Clin Oncol. 2001 Jul 15;19(14):3385-91 [11454886.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2073-8 [16648508.001]
  • [Cites] J Pain Symptom Manage. 2003 Jul;26(1):604-14 [12850643.001]
  • [Cites] Support Care Cancer. 2008 Aug;16(8):943-6 [18071764.001]
  • [Cites] Oncologist. 2000;5(5):353-60 [11040270.001]
  • [Cites] JAMA. 2007 Jan 17;297(3):295-304 [17227981.001]
  • [Cites] J Palliat Med. 2005 Dec;8(6):1144-9 [16351527.001]
  • [Cites] Eur J Cancer. 2007 Apr;43(6):1030-6 [17336052.001]
  • [Cites] J Clin Oncol. 1993 Mar;11(3):570-9 [8445433.001]
  • [Cites] J Palliat Care. 1991 Summer;7(2):6-9 [1714502.001]
  • [Cites] Sch Inq Nurs Pract. 2000 Winter;14(4):275-90; discussion 291-8 [11372188.001]
  • [Cites] J Psychiatr Res. 1975 Nov;12(3):189-98 [1202204.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4439-43 [14645434.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):528-38 [11900238.001]
  • [Cites] J Pain Symptom Manage. 1992 May;7(4):192-5 [1517640.001]
  • [Cites] Cancer. 2000 May 1;88(9):2164-71 [10813730.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):743-53 [10673515.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):377-82 [15558809.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1319-28 [11870175.001]
  • [Cites] Ann Oncol. 2000 May;11(5):561-7 [10907949.001]
  • [Cites] J Pain Symptom Manage. 2001 Jun;21(6):456-66 [11397603.001]
  • [Cites] Semin Hematol. 1997 Jul;34(3 Suppl 2):4-12 [9253778.001]
  • [Cites] J Pain Symptom Manage. 2006 Mar;31(3):229-41 [16563317.001]
  • (PMID = 18504622.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01CA1222292.01; United States / NCI NIH HHS / CA / R01CA124481-01; United States / NINR NIH HHS / NR / R01NR010162-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


63. Mel JR Sr, Ramos M, Cueva J, Castellanos J, Almanza C: Pilot study with pegylated liposomal doxorubicin (PLD) and docetaxel as first-line treatment in patients with metastatic breast cancer (MBC). J Clin Oncol; 2009 May 20;27(15_suppl):e12002

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot study with pegylated liposomal doxorubicin (PLD) and docetaxel as first-line treatment in patients with metastatic breast cancer (MBC).
  • METHODS: Pts ≥ 18 years with histologically confirmed breast cancer, advanced disease, PS ≥ 60%, LVEF> 50%, adequate bone marrow, renal and hepatic function were included.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964260.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Bakitas M, Lyons KD, Hegel MT, Balan S, Brokaw FC, Seville J, Hull JG, Li Z, Tosteson TD, Byock IR, Ahles TA: Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. JAMA; 2009 Aug 19;302(7):741-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial.
  • CONTEXT: There are few randomized controlled trials on the effectiveness of palliative care interventions to improve the care of patients with advanced cancer.
  • OBJECTIVE: To determine the effect of a nursing-led intervention on quality of life, symptom intensity, mood, and resource use in patients with advanced cancer.
  • DESIGN, SETTING, AND PARTICIPANTS: Randomized controlled trial conducted from November 2003 through May 2008 of 322 patients with advanced cancer in a rural, National Cancer Institute-designated comprehensive cancer center in New Hampshire and affiliated outreach clinics and a VA medical center in Vermont.
  • INTERVENTIONS: A multicomponent, psychoeducational intervention (Project ENABLE [Educate, Nurture, Advise, Before Life Ends]) conducted by advanced practice nurses consisting of 4 weekly educational sessions and monthly follow-up sessions until death or study completion (n = 161) vs usual care (n = 161).
  • RESULTS: A total of 322 participants with cancer of the gastrointestinal tract (41%; 67 in the usual care group vs 66 in the intervention group), lung (36%; 58 vs 59), genitourinary tract (12%; 20 vs 19), and breast (10%; 16 vs 17) were randomized.

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2008 Oct 8;300(14):1665-73 [18840840.001]
  • [Cites] Arch Intern Med. 2008 Sep 8;168(16):1783-90 [18779466.001]
  • [Cites] J Clin Oncol. 2009 Jan 10;27(2):206-13 [19064979.001]
  • [Cites] Palliat Support Care. 2009 Mar;7(1):75-86 [19619377.001]
  • [Cites] J Pain Symptom Manage. 2009 Jan;37(1):23-32 [18504093.001]
  • [Cites] J Clin Oncol. 2008 Aug 10;26(23):3860-6 [18688053.001]
  • [Cites] Ann Intern Med. 2000 May 16;132(10):825-32 [10819707.001]
  • [Cites] JAMA. 2000 Nov 15;284(19):2476-82 [11074777.001]
  • [Cites] Pharmacoeconomics. 2000 Nov;18(5):419-23 [11151395.001]
  • [Cites] J Pain Symptom Manage. 2001 Jul;22(1):584-90 [11516600.001]
  • [Cites] J Pain Symptom Manage. 2001 Sep;22(3):727-37 [11532586.001]
  • [Cites] Health Aff (Millwood). 2001 Nov-Dec;20(6):64-78 [11816692.001]
  • [Cites] Cancer Control. 2001 Nov-Dec;8(6 Suppl 2):88-93 [11760564.001]
  • [Cites] Qual Life Res. 2002 May;11(3):207-21 [12074259.001]
  • [Cites] JAMA. 2003 Jun 18;289(23):3106-16 [12813116.001]
  • [Cites] J Palliat Med. 2003 Oct;6(5):699-705 [14622449.001]
  • [Cites] Arch Intern Med. 2004 Jan 12;164(1):83-91 [14718327.001]
  • [Cites] J Palliat Med. 2004 Feb;7(1):119-34 [15000796.001]
  • [Cites] BMJ. 2004 Mar 13;328(7440):607 [15016692.001]
  • [Cites] Oncol Nurs Forum. 2004 Mar-Apr;31(2):313-9 [15017447.001]
  • [Cites] J Palliat Med. 2004 Apr;7(2):363-72 [15130218.001]
  • [Cites] N Engl J Med. 2004 Jun 17;350(25):2582-90 [15201415.001]
  • [Cites] Health Serv Res. 2004 Aug;39(4 Pt 1):1005-26 [15230939.001]
  • [Cites] Lancet. 1984 Apr 21;1(8382):890-4 [6143195.001]
  • [Cites] J Palliat Care. 1991 Summer;7(2):6-9 [1714502.001]
  • [Cites] J Am Geriatr Soc. 1992 Jul;40(7):697-702 [1607586.001]
  • [Cites] BMJ. 1992 Nov 28;305(6865):1317-22 [1483075.001]
  • [Cites] Psychol Rep. 1996 Dec;79(3 Pt 1):1059-69 [8969117.001]
  • [Cites] Cancer Pract. 1997 May-Jun;5(3):147-54 [9171550.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1986-96 [9586919.001]
  • [Cites] Hosp J. 1998;13(1-2):71-87 [9644394.001]
  • [Cites] Jt Comm J Qual Improv. 1998 Oct;24(10):513-7 [9801950.001]
  • [Cites] Eff Clin Pract. 1998 Aug-Sep;1(1):2-4 [10345255.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2637-44 [15728219.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2588-9 [15728223.001]
  • [Cites] J Altern Complement Med. 2005;11 Suppl 1:S7-15 [16332190.001]
  • [Cites] J Palliat Med. 2006 Feb;9(1):137-51 [16430353.001]
  • [Cites] J Pain Symptom Manage. 2006 Mar;31(3):270-84 [16563321.001]
  • [Cites] Health Promot Int. 2006 Sep;21(3):245-55 [16751630.001]
  • [Cites] Health Qual Life Outcomes. 2006;4:54 [16925807.001]
  • [Cites] Am J Manag Care. 2007 Feb;13(2):84-92 [17286528.001]
  • [Cites] J Pain Symptom Manage. 2007 Mar;33(3):238-46 [17349493.001]
  • [Cites] J Palliat Med. 2007 Apr;10(2):381-9 [17472510.001]
  • [Cites] J Clin Nurs. 2007 Mar;16(3A):95-104 [17518874.001]
  • [Cites] J Clin Oncol. 2007 Jun 10;25(17):2377-82 [17557950.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):196-202 [17546575.001]
  • [Cites] J Pain Symptom Manage. 2007 Jul;34(1 Suppl):S7-S19 [17532180.001]
  • [Cites] J Pain Symptom Manage. 2007 Aug;34(2):120-5 [17583469.001]
  • [Cites] Prev Med. 2007 Oct;45(4):252-61 [17643481.001]
  • [Cites] Clin Cancer Res. 2008 Apr 1;14(7):2111-8 [18381952.001]
  • [Cites] JAMA. 2008 Apr 9;299(14):1698-709 [18398082.001]
  • [Cites] Cancer. 2008 Apr 15;112(8):1854-61 [18306393.001]
  • [Cites] BMC Psychiatry. 2008;8:60 [18647396.001]
  • [Cites] J Clin Oncol. 2008 Aug 10;26(23):3832-7 [18688049.001]
  • [CommentIn] Evid Based Nurs. 2010 Feb;13(1):9-10 [20179053.001]
  • [CommentIn] JAMA. 2009 Dec 16;302(23):2551; author reply 2551 [20009052.001]
  • (PMID = 19690306.001).
  • [ISSN] 1538-3598
  • [Journal-full-title] JAMA
  • [ISO-abbreviation] JAMA
  • [Language] ENG
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00253383
  • [Grant] United States / NCI NIH HHS / CA / R01 CA101704; United States / NCI NIH HHS / CA / P30 CA023108; United States / NINR NIH HHS / NR / R01 NR011871; United States / NINR NIH HHS / NR / T32 NR008346; United States / NINR NIH HHS / NR / T32NR008346
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS458527; NLM/ PMC3657724
  •  go-up   go-down


65. Clayton JM, Butow PN, Tattersall MH, Devine RJ, Simpson JM, Aggarwal G, Clark KJ, Currow DC, Elliott LM, Lacey J, Lee PG, Noel MA: Randomized controlled trial of a prompt list to help advanced cancer patients and their caregivers to ask questions about prognosis and end-of-life care. J Clin Oncol; 2007 Feb 20;25(6):715-23
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized controlled trial of a prompt list to help advanced cancer patients and their caregivers to ask questions about prognosis and end-of-life care.
  • PURPOSE: To determine whether provision of a question prompt list (QPL) influences advanced cancer patients'/caregivers' questions and discussion of topics relevant to end-of-life care during consultations with a palliative care (PC) physician.
  • Consecutive eligible patients with advanced cancer referred to 15 PC physicians from nine Australian PC services were invited to participate.
  • CONCLUSION: Providing a QPL and physician endorsement of its use assists terminally ill cancer patients and their caregivers to ask questions and promotes discussion about prognosis and end-of-life issues, without creating patient anxiety or impairing satisfaction.

  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Oncol. 2007 Oct;4(10):562-3 [17700555.001]
  • (PMID = 17308275.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


66. Kimura R, Hashiguchi S, Kawa M, Miyashita M, Sasahara T, Shirai Y, Kazuma K: Pain management and related factors in advanced cancer patients who initiated opioid therapy in an outpatient setting. Palliat Support Care; 2005 Dec;3(4):301-9
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pain management and related factors in advanced cancer patients who initiated opioid therapy in an outpatient setting.
  • OBJECTIVE: The aim of this study was to clarify the state of pain management in Japanese patients with advanced cancer who initiated opioid therapy in an outpatient setting.
  • SIGNIFICANCE OF RESULTS: Result of this study indicated insufficient pain relief at an outpatients setting with advanced cancer patients.

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17039985.001).
  • [ISSN] 1478-9515
  • [Journal-full-title] Palliative & supportive care
  • [ISO-abbreviation] Palliat Support Care
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Analgesics, Opioid
  •  go-up   go-down


67. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, Ashkenazi A, Jubb AM, Mendelson DS: Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol; 2010 Jun 10;28(17):2839-46
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.
  • Recombinant human Apo2L/TRAIL (rhApo2L/TRAIL) has broad potential as a cancer therapy.
  • To the best of our knowledge, this is the first in-human clinical trial to assess the safety, tolerability, pharmacokinetics, and antitumor activity of multiple intravenous doses of rhApo2L/TRAIL in patients with advanced cancer.
  • PATIENTS AND METHODS: This phase I, open-label, dose-escalation study treated patients with advanced cancer with rhApo2L/TRAIL doses ranging from 0.5 to 30 mg/kg/d, with parallel dose escalation for patients without liver metastases and with normal liver function (cohort 1) and for patients with liver metastases and normal or mildly abnormal liver function (cohort 2).

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20458040.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Recombinant Proteins; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human
  •  go-up   go-down


68. Ishigami H, Kitayama J, Kaisaki S, Hidemura A, Kato M, Otani K, Kamei T, Soma D, Miyato H, Yamashita H, Nagawa H: Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. J Clin Oncol; 2009 May 20;27(15_suppl):4542

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis.
  • : 4542 Background: A phase II study to evaluate the efficacy and tolerability of weekly intravenous and intraperitoneal paclitaxel combined with S-1 was performed in gastric cancer patients with peritoneal metastasis.
  • METHODS: Gastric cancer patients with peritoneal dissemination and/or cancer cells on peritoneal cytology were enrolled.
  • Secondary endpoints were the response rate, efficacy against malignant ascites and safety.
  • Malignant ascites disappeared or decreased in 13 of 21 (62%) patients.
  • CONCLUSIONS: Combination chemotherapy of intravenous and intraperitoneal paclitaxel with S-1 is well tolerated and active in gastric cancer patients with peritoneal metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963015.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Tang P, Gill S, Au HJ, Chen EX, Hedley D, Leroux M, Wang L, Moore MJ: Phase II trial of erlotinib in advanced pancreatic cancer (PC). J Clin Oncol; 2009 May 20;27(15_suppl):4609

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of erlotinib in advanced pancreatic cancer (PC).
  • METHODS: Erlotinib was given at an initial dose of 150 mg/day to eligible pts with locally advanced (LA) or metastatic PC who had progressed or were unable to tolerate gemcitabine-based chemotherapy.
  • CONCLUSIONS: Erlotinib is associated with prolonged stable disease in a subset of pts with advanced refractory PC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964176.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Soto-Cárdenas MJ, Pelayo-García G, Rodríguez-Camacho A, Segura-Fernández E, Mogollo-Galván A, Giron-Gonzalez JA: Venous thromboembolism in patients with advanced cancer under palliative care: additional risk factors, primary/secondary prophylaxis and complications observed under normal clinical practice. Palliat Med; 2008 Dec;22(8):965-8
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Venous thromboembolism in patients with advanced cancer under palliative care: additional risk factors, primary/secondary prophylaxis and complications observed under normal clinical practice.
  • Patients with advanced cancer under palliative care (PC) and with VTE, were reviewed during the three years before the study.
  • In PC patients with advanced cancer, VTE is a serious complication that conditions control of symptoms.

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18952751.001).
  • [ISSN] 1477-030X
  • [Journal-full-title] Palliative medicine
  • [ISO-abbreviation] Palliat Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Fibrinolytic Agents; 0 / Heparin, Low-Molecular-Weight
  •  go-up   go-down


71. Carducci MA, Armstrong DK, Collins C, Wang T, Schaefer S, Ermisch S, Musib LC, Nicol S, Thornton DE, Zhang Z: Phase I study of enzastaurin (ENZ) and bevacizumab (BV) in patients with advanced cancer: Safety, pharmacokinetics (PK), and response assessment. J Clin Oncol; 2009 May 20;27(15_suppl):3517

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of enzastaurin (ENZ) and bevacizumab (BV) in patients with advanced cancer: Safety, pharmacokinetics (PK), and response assessment.
  • METHODS: Eligible patients (pts) had advanced cancer, adequate organ function and no co-morbidities for increased risk of drug-related toxicities.
  • RESULTS: 43 pts (21 with ovarian cancer) are evaluable for toxicity.
  • CONCLUSIONS: The addition of ENZ to BV in any of the currently approved BV dosing schedules is well tolerated and clinically active in advanced cancer pts.
  • The combination of ENZ / BV demonstrates encouraging activity, specifically in our population of ovarian cancer pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961299.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Sideras K, Schaefer PL, Okuno SH, Sloan JA, Kutteh L, Fitch TR, Dakhil SR, Levitt R, Alberts SR, Morton RF, Rowland KM, Novotny PJ, Loprinzi CL: Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc; 2006 Jun;81(6):758-67
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial.
  • OBJECTIVE: To prospectively assess whether low-molecular-weight heparin (LMWH) provides a survival benefit in patients with advanced cancer.
  • PATIENTS AND METHODS: Between December 1998 and June 2001, we performed a randomized controlled study of patients with advanced cancer.

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16770976.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-15083; United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-35101; United States / NCI NIH HHS / CA / CA-35195; United States / NCI NIH HHS / CA / CA-35431; United States / NCI NIH HHS / CA / CA-37404; United States / NCI NIH HHS / CA / CA-37417; United States / NCI NIH HHS / CA / CA-52352; United States / NCI NIH HHS / CA / CA-60276; United States / NCI NIH HHS / CA / CA-63826
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; S79O08V79F / Dalteparin
  •  go-up   go-down


73. Heigener DF, Wiesner C, Aultman R: A cost analysis of treatment with bevacizumab plus cisplatin and gemcitabine (BCG) versus cetuximab plus vinorelbine and cisplatin (CVC) in patients with advanced or recurrent non-small cell lung cancer (NSCLC) in Germany. J Clin Oncol; 2009 May 20;27(15_suppl):e17553

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A cost analysis of treatment with bevacizumab plus cisplatin and gemcitabine (BCG) versus cetuximab plus vinorelbine and cisplatin (CVC) in patients with advanced or recurrent non-small cell lung cancer (NSCLC) in Germany.
  • : e17553 Background: Although new treatment options for advanced NSCLC can offer improved survival over standard treatment with chemotherapy (CT) they should also offer value for money.
  • Bevacizumab (BEV), a humanized monoclonal antibody (MAb) directed against vascular endothelial growth factor when combined with CT increases overall survival (median 13.6 months in the AVAiL study) and progression-free survival (PFS) in patients with advanced NSCLC when compared with CT alone.
  • METHODS: A Markov model was used to compare drug and administration costs associated with treating advanced or recurrent NSCLC with either BCG or CVC.
  • CONCLUSIONS: Targeted therapy using BEV is less costly than CTX in Germany and thus, from a budget perspective, offers the best value for money strategy for improving outcomes in patients with advanced NSCLC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963877.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Bowman KF, Rose JH, Radziewicz RM, O'Toole EE, Berila RA: Family caregiver engagement in a coping and communication support intervention tailored to advanced cancer patients and families. Cancer Nurs; 2009 Jan-Feb;32(1):73-81
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Family caregiver engagement in a coping and communication support intervention tailored to advanced cancer patients and families.
  • We describe family caregiver (FCG) participation in a tailored coping and communication support intervention for advanced cancer patients and families.
  • Findings will guide modification and dissemination of this intervention primarily in cancer clinics for the underserved.

  • MedlinePlus Health Information. consumer health - Caregivers.
  • MedlinePlus Health Information. consumer health - Family Issues.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19104204.001).
  • [ISSN] 1538-9804
  • [Journal-full-title] Cancer nursing
  • [ISO-abbreviation] Cancer Nurs
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA102828; United States / NCI NIH HHS / CA / R01-CA10282
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


75. Dewey A, Dean T: Assessment and monitoring of nutritional status in patients with advanced cancer: part 1. Int J Palliat Nurs; 2007 Jun;13(6):258-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment and monitoring of nutritional status in patients with advanced cancer: part 1.
  • Using a qualitative approach, this study set out to explore nurses' management of patients with advanced cancer, weight loss and eating-associated problems.
  • Extreme weight loss is commonly seen in patients with incurable solid tumour cancer and, to date, it has proved difficult to manage successfully.
  • Many nurses were reluctant to initiate conversations with cancer patients about weight loss, but instead waited for patients and relatives to raise their concerns.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17851381.001).
  • [ISSN] 1357-6321
  • [Journal-full-title] International journal of palliative nursing
  • [ISO-abbreviation] Int J Palliat Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


76. Rowlands J, Noble S: How does the environment impact on the quality of life of advanced cancer patients? A qualitative study with implications for ward design. Palliat Med; 2008 Sep;22(6):768-74

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How does the environment impact on the quality of life of advanced cancer patients? A qualitative study with implications for ward design.
  • The aim of this study is to explore the views of patients with advanced cancer on the effect the ward environment has on their overall well-being.
  • Semi-structured interviews exploring the experiences of 12 inpatients at a regional cancer centre were recorded and transcribed verbatim.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18715977.001).
  • [ISSN] 1477-030X
  • [Journal-full-title] Palliative medicine
  • [ISO-abbreviation] Palliat Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


77. Bausewein C, Booth S, Gysels M, Kühnbach R, Haberland B, Higginson IJ: Individual breathlessness trajectories do not match summary trajectories in advanced cancer and chronic obstructive pulmonary disease: results from a longitudinal study. Palliat Med; 2010 Dec;24(8):777-86
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Individual breathlessness trajectories do not match summary trajectories in advanced cancer and chronic obstructive pulmonary disease: results from a longitudinal study.
  • Breathlessness is a distressing symptom in advanced disease.
  • This study aimed to describe and compare the summary and individual trajectories of breathlessness and overall symptom burden over time and towards the end of life following patients with advanced cancer or severe chronic obstructive pulmonary disease (COPD) in inpatient and outpatient health care settings in Germany.
  • Forty-nine cancer and 60 COPD patients were included.
  • Thirty out of the 49 cancer and 6/60 COPD patients died, 7/49 cancer and 20/60 COPD patients dropped out due to physical deterioration or questionnaire fatigue.
  • In cancer patients, breathlessness increased towards death.
  • Twenty-one cancer and 43 COPD patients provided data for individual breathlessness trajectories.


78. Paripati H, Tong W, Karlin NJ, Dueck AC, Ross HJ: Treatment and outcomes of elderly versus younger patients with advanced NSCLC at Mayo Clinic Arizona (MCA). J Clin Oncol; 2009 May 20;27(15_suppl):e19047

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and outcomes of elderly versus younger patients with advanced NSCLC at Mayo Clinic Arizona (MCA).
  • : e19047 Background: Non-small cell lung cancer (NSCLC) is predominantly a disease of the elderly.
  • Most patients (pts) present with incurable advanced disease, but chemotherapy for good performance status (PS) pts improves quality and quantity of life.
  • METHODS: All analytic MCA Cancer Registry pts with stage IV NSCLC from 1998-2007 were retrospectively reviewed for type of therapy and outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962100.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Smith M, Kutner J, Hemphill L, Yamashita T, Felton S: Developing treatment and control conditions in a clinical trial of massage therapy for advanced cancer. J Soc Integr Oncol; 2007;5(4):139-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Developing treatment and control conditions in a clinical trial of massage therapy for advanced cancer.
  • The purpose of this article is to describe the challenges faced by a research team in developing treatment and control conditions in a study of the efficacy of massage therapy for advanced cancer.

  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19087757.001).
  • [ISSN] 1715-894X
  • [Journal-full-title] Journal of the Society for Integrative Oncology
  • [ISO-abbreviation] J Soc Integr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


80. Walsh D, Perin ML, McIver B: Parenteral morphine prescribing patterns among inpatients with pain from advanced cancer: a prospective survey of intravenous and subcutaneous use. Am J Hosp Palliat Care; 2006 Oct-Nov;23(5):353-9
Hazardous Substances Data Bank. MORPHINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parenteral morphine prescribing patterns among inpatients with pain from advanced cancer: a prospective survey of intravenous and subcutaneous use.
  • Prescribing patterns for parenteral morphine for symptom control in advanced cancer were studied in 50 consecutive hospital admissions (27 men, 23 women, median age, 62 years).
  • These patterns of parenteral morphine application reflect the complexity of the challenge presented by the various cancer pain syndromes.

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17060302.001).
  • [ISSN] 1049-9091
  • [Journal-full-title] The American journal of hospice & palliative care
  • [ISO-abbreviation] Am J Hosp Palliat Care
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 76I7G6D29C / Morphine
  •  go-up   go-down


81. Dy SM, Apostol CC: Evidence-based approaches to other symptoms in advanced cancer. Cancer J; 2010 Sep-Oct;16(5):507-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence-based approaches to other symptoms in advanced cancer.
  • Dyspnea, nausea and vomiting, anorexia, fatigue, and sleep disturbances are common and distressing in advanced cancer.
  • The strongest evidence supports metoclopramide for cancer-related nausea and octreotide for bowel obstruction.
  • For insomnia, evidence supports cognitive-behavioral therapy in cancer; no sleep agents have superior effectiveness.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20890148.001).
  • [ISSN] 1540-336X
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  •  go-up   go-down


82. Koffman J, Morgan M, Edmonds P, Speck P, Higginson I: Cultural meanings of pain: a qualitative study of Black Caribbean and White British patients with advanced cancer. Palliat Med; 2008 Jun;22(4):350-9
MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cultural meanings of pain: a qualitative study of Black Caribbean and White British patients with advanced cancer.
  • Pain is a common cancer-related symptom, but little research has been conducted that explores the meanings of this symptom across different ethnic groups.
  • This study involved qualitative interviews to explore and compare the meanings of pain among 26 Black Caribbean and 19 White patients with advanced cancer.
  • A total of 23/26 Black Caribbean and 15/19 White patients reported cancer-related pain.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18541639.001).
  • [ISSN] 0269-2163
  • [Journal-full-title] Palliative medicine
  • [ISO-abbreviation] Palliat Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


83. Radziewicz RM, Rose JH, Bowman KF, Berila RA, O'Toole EE, Given B: Establishing treatment fidelity in a coping and communication support telephone intervention for aging patients with advanced cancer and their family caregivers. Cancer Nurs; 2009 May-Jun;32(3):193-202
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishing treatment fidelity in a coping and communication support telephone intervention for aging patients with advanced cancer and their family caregivers.
  • A randomized controlled trial of a nurse-delivered coping and communication support (CCS) intervention tailored to the preferences of middle-aged and older patients with advanced cancer and their family caregivers is tested for its value in improving outcomes for quality cancer care.

  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19295420.001).
  • [ISSN] 1538-9804
  • [Journal-full-title] Cancer nursing
  • [ISO-abbreviation] Cancer Nurs
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA102828; United States / NCI NIH HHS / CA / R01-CA10282
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 28
  •  go-up   go-down


84. Berardi R, Mandolesi A, Onofri A, Maccaroni E, Mantello G, Bearzi I, Scartozzi M, Pierantoni C, Marmorale C, Cascinu S: Nuclear factor-kB (NF-kB), p53, survivin, Ki-67, and Bcl-2 as prognostic factors in locally advanced rectal cancer patients receiving radiochemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):e22062

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear factor-kB (NF-kB), p53, survivin, Ki-67, and Bcl-2 as prognostic factors in locally advanced rectal cancer patients receiving radiochemotherapy.
  • The aim of our analysis was to investigate the importance of their expression, as prognostic factors in patients with locally advanced rectal cancer patients receiving receiving neoadjuvant radiochemotherapy Methods: We analyzed the expression of NF-kB, p53, Survivin, Ki-67 and Bcl-2 in patients with locally advanced rectal cancer who underwent neoadjuvant treatment (radiotherapy ± chemotherapy) at our Department Results: Seventy-four patients were eligible for our analysis.
  • Moreover a high expression of Ki-67 and a low expression of bcl-2 were associated with a better TTP Conclusions: Our results suggest that NF-kB, bcl-2 and Ki-67 could represent important parameters able to predict the outcome in patients receiving neoadjuvant treatment for rectal cancer.
  • This could be useful in order to select patients to receive adjuvant chemotherapy after neoadjuvant treatment and surgery for locally advanced rectal cancer, intensifying the adjuvant therapy in some groups of patients and obviating the use of the some drugs (i.e. those involving NF-kB in their mechanism of action) in selected patients No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963205.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Murata S, Naito H, Yamamoto H, Mekata E, Shimizu T, Shiomi H, Naka S, Abe H, Kurumi Y, Tani T: Phase II trial of adjuvant hyperthermic intraperitoneal chemotherapy with three drugs for the prophylactic treatment of carcinomatosis after resection of advanced gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15588

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of adjuvant hyperthermic intraperitoneal chemotherapy with three drugs for the prophylactic treatment of carcinomatosis after resection of advanced gastric cancer.
  • : e15588 Background: This prospective study was performed to assess the efficacy and safety of hyperthermic intraperitoneal chemotherapy (HIPEC) with three drugs in patients with curative resection of T3 or T4 advanced gastric cancer.
  • METHODS: Patients with curative resection of clinically T3 or T4 advanced gastric cancer were required to be under 75 years of age and to have adequate organ function.
  • After the curative resection of gastric cancer with D2 lymph node dissection and the reconstruction of the alimentary tract, HIPEC was carried out for 30 minutes with 50mg of CDDP, 10mg of MMC, and 1000mg of 5-FU in 5 L saline maintained at 42-43°C.
  • CONCLUSIONS: The present study suggests that HIPEC with three drugs after curative resection of advanced gastric primary cancer is associated with improved overall survival with an acceptable morbidity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962346.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Ma S, Xu Y, Yu X: Concomitant pemetrexed/carboplatin chemotherapy with 3-D conformal radiotherapy followed by pemetrexed/carboplatin consolidation chemotherapy in locally advanced non-small cell lung cancer in a Chinese population. J Clin Oncol; 2009 May 20;27(15_suppl):e18502

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant pemetrexed/carboplatin chemotherapy with 3-D conformal radiotherapy followed by pemetrexed/carboplatin consolidation chemotherapy in locally advanced non-small cell lung cancer in a Chinese population.
  • : e18502 Background: Pemetrexed in combination with carboplatin has been shown to have promising activity, as well as superior toxicity profile in advanced non-small cell lung cancer(NSCLC).
  • Radiotherapy(RT) has been shown to improve survival of patients with locally advanced NSCLC when combined with other platin doublets.
  • This phase II study of concomitant pemetrexed/carboplatin chemotherapy(CT) with 3-D conformal RT followed by pemetrexed/carboplatin consolidation CT in locally advanced NSCLC was designed to evaluate the efficacy and safety of this novel regimen.
  • CONCLUSIONS: This preliminary data suggests that concomitant treatment was well tolerated, with promising activity and a significant improvement of QoL in a Chinese population with locally advanced NSCLC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962399.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Lee JJ, Lee JJ: A phase II study of an herbal decoction that includes Astragali radix for cancer-associated anorexia in patients with advanced cancer. Integr Cancer Ther; 2010 Mar;9(1):24-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of an herbal decoction that includes Astragali radix for cancer-associated anorexia in patients with advanced cancer.
  • HYPOTHESIS: Anorexia and cancer cachexia produce significant loss of adipose tissue and muscle mass and eventually reduce survival in cancer patients.
  • STUDY DESIGN: This phase II study was conducted to assess the efficacy and the safety of an herbal decoction with Astragali radix in patients with anorexia in advanced cancer.
  • METHODS: All patients with histologic evidence of an incurable malignancy had a weight loss of at least 5% during the preceding 6 months and a patient-estimated severe anorexia.The herbal decoction was administered 30 minutes after meals, three times a day for 3 weeks.The score of appetite, body weight, the cytokines, IL-1beta, IL-6, TNF-alpha, and anthropometric measurements were assessed.
  • This herbal decoction shows some potential for management of cancer-related anorexia.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LACTIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20150220.001).
  • [ISSN] 1552-695X
  • [Journal-full-title] Integrative cancer therapies
  • [ISO-abbreviation] Integr Cancer Ther
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Astragali compound; 0 / Cytokines; 0 / Drugs, Chinese Herbal; 33X04XA5AT / Lactic Acid
  •  go-up   go-down


88. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, Olgac S, Marks PA, Scher H, Richon VM: Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol; 2005 Jun 10;23(17):3923-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
  • PURPOSE: To determine the safety, dosing schedules, pharmacokinetic profile, and biologic effect of orally administered histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with advanced cancer.

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Vorinostat .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2003 Jan 10;112(1):11-7 [12526789.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] FEBS Lett. 2001 Jun 22;499(3):199-204 [11423116.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jul;86(7):3430-5 [11443220.001]
  • [Cites] Gene Expr. 1996;5(4-5):245-53 [8723390.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2860-5 [11854457.001]
  • [Cites] Am J Respir Cell Mol Biol. 2001 Nov;25(5):562-8 [11713097.001]
  • [Cites] J Clin Oncol. 1990 May;8(5):813-9 [2185339.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Adv Cancer Res. 2004;91:137-68 [15327890.001]
  • [Cites] Curr Opin Genet Dev. 2002 Apr;12(2):198-209 [11893494.001]
  • [Cites] Nat Genet. 2002 Jun;31(2):141-9 [11992124.001]
  • [Cites] Genome Biol. 2002;3(5):reviews0006 [12049668.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11700-5 [12189205.001]
  • [Cites] Nat Genet. 2002 Dec;32(4):606-13 [12402037.001]
  • [Cites] Blood. 2003 Apr 15;101(8):2914-23 [12515714.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3578-88 [14506144.001]
  • [Cites] Endocrinology. 2004 Jun;145(6):2865-75 [14976143.001]
  • (PMID = 15897550.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA092629; United States / NCI NIH HHS / CA / R21 CA096228; United States / NCI NIH HHS / CA / CA96228-0
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 58IFB293JI / vorinostat
  • [Other-IDs] NLM/ NIHMS18169; NLM/ PMC1855284
  •  go-up   go-down


89. Nekolaichuk CL, Fainsinger RL, Lawlor PG: A validation study of a pain classification system for advanced cancer patients using content experts: the Edmonton Classification System for Cancer Pain. Palliat Med; 2005 Sep;19(6):466-76
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A validation study of a pain classification system for advanced cancer patients using content experts: the Edmonton Classification System for Cancer Pain.
  • The purpose of this study was to gather construct validity evidence for a pain classification system for advanced cancer patients using content experts.
  • To reflect its intended use as a classification system, the name of the instrument was changed to the Edmonton Classification System for Cancer Pain (ECS-CP).

  • MedlinePlus Health Information. consumer health - Pain.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16218159.001).
  • [ISSN] 0269-2163
  • [Journal-full-title] Palliative medicine
  • [ISO-abbreviation] Palliat Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  •  go-up   go-down


90. Briasoulis E, Golfinopoulos V, Karina M, Papakostas P, Pavlidis N, Fountzilas G: Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study. Anticancer Drugs; 2010 Sep;21(8):785-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study.
  • This trial aimed to define a recommended safe dose (RSD) of weekly paclitaxel and irinotecan combined with carboplatin in patients with advanced cancer.
  • Patients with advanced cancer were eligible for this trial.
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neoplasm Staging. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20647930.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 7673326042 / irinotecan; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


91. Agar M, To T, Plummer J, Abernethy A, Currow D: Anti-cholinergic load, health care utilization, and survival in people with advanced cancer: a pilot study. J Palliat Med; 2010 Jun;13(6):745-52
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-cholinergic load, health care utilization, and survival in people with advanced cancer: a pilot study.
  • Anti-cholinergic load associated with medication increases as death approaches in those with advanced cancer, yet little is known about associated adverse outcomes in this setting.
  • METHODS: A substudy of 112 participants in a randomised control trial who had cancer and an Australia modified Karnofsky Performance Scale (AKPS) score (AKPS) of 60 or above, explored survival and health service utilisation; with anti-cholinergic load calculated using the Clinician Rated Anti-cholinergic Scale (modified version) longitudinally to death.
  • [MeSH-major] Cholinergic Antagonists / therapeutic use. Health Services / utilization. Neoplasm Staging. Neoplasms / drug therapy. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20597708.001).
  • [ISSN] 1557-7740
  • [Journal-full-title] Journal of palliative medicine
  • [ISO-abbreviation] J Palliat Med
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cholinergic Antagonists
  •  go-up   go-down


92. Curtis JR, Engelberg R, Young JP, Vig LK, Reinke LF, Wenrich MD, McGrath B, McCown E, Back AL: An approach to understanding the interaction of hope and desire for explicit prognostic information among individuals with severe chronic obstructive pulmonary disease or advanced cancer. J Palliat Med; 2008 May;11(4):610-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An approach to understanding the interaction of hope and desire for explicit prognostic information among individuals with severe chronic obstructive pulmonary disease or advanced cancer.
  • METHODS: We conducted in-depth longitudinal qualitative interviews with patients with either advanced cancer or severe chronic obstructive pulmonary disease (COPD), along with their family, physicians, and nurses.


93. Hishinuma S, Ogata Y, Tomikawa M, Ozawa I: Stomach-preserving distal pancreatectomy with combined resection of the celiac artery: radical procedure for locally advanced cancer of the pancreatic body. J Gastrointest Surg; 2007 Jun;11(6):743-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stomach-preserving distal pancreatectomy with combined resection of the celiac artery: radical procedure for locally advanced cancer of the pancreatic body.
  • To enhance the resectability of cancer of the pancreatic body, a new surgical technique should be developed.
  • Of 25 patients with cancer of the pancreatic body who underwent distal pancreatectomy with curative intent, seven with cancer invasion around the celiac artery underwent stomach-preserving distal pancreatectomy with combined resection of the celiac artery.
  • The present study suggests that this surgical procedure is a rational approach to locally advanced pancreatic body cancer invading around the celiac artery.
  • In view of the feasibility of this procedure, it can also be adopted for less advanced cancer of the pancreatic body to enhance local control and survival.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatobiliary Pancreat Dis Int. 2003 Nov;2(4):622-5 [14627533.001]
  • [Cites] Surg Today. 2003;33(11):873-8 [14605963.001]
  • [Cites] Cancer. 1996 Jun 1;77(11):2240-5 [8635090.001]
  • [Cites] Ann Surg. 1984 Apr;199(4):418-25 [6712317.001]
  • [Cites] Cancer. 1953 Jul;6(4):704-7 [13059764.001]
  • [Cites] Am J Surg. 1992 Jul;164(1):26-31 [1378243.001]
  • [Cites] Langenbecks Arch Surg. 2003 Apr;388(2):101-6 [12684805.001]
  • [Cites] Am J Surg. 2006 Sep;192(3):330-5 [16920427.001]
  • [Cites] J Gastrointest Surg. 2006 Apr;10(4):511-8 [16627216.001]
  • [Cites] Hepatogastroenterology. 2005 Jul-Aug;52(64):1090-1 [16001636.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2005;12 (1):55-60 [15754101.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2005;12(3):235-42 [15995813.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(2):183-7 [10982611.001]
  • [Cites] J Gastrointest Surg. 2003 Dec;7(8):946-52; discussion 952 [14675703.001]
  • [Cites] J Gastrointest Surg. 2005 Apr;9(4):503-7 [15797231.001]
  • [Cites] Hepatogastroenterology. 1997 Mar-Apr;44(14):387-93 [9164507.001]
  • [Cites] Int J Pancreatol. 1997 Aug;22(1):15-21 [9387020.001]
  • [Cites] Hepatogastroenterology. 1999 Jul-Aug;46(28):2628-30 [10522054.001]
  • [Cites] J Gastrointest Surg. 2005 Sep-Oct;9(7):922-7 [16137585.001]
  • (PMID = 17417712.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Rustin GJ, Shreeves G, Nathan PD, Gaya A, Ganesan TS, Wang D, Boxall J, Poupard L, Chaplin DJ, Stratford MR, Balkissoon J, Zweifel M: A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br J Cancer; 2010 Apr 27;102(9):1355-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.
  • METHODS: Patients with advanced cancer refractory to standard therapy were treated with CA4P as a 10-min infusion, 20 h before carboplatin, paclitaxel, or paclitaxel, followed by carboplatin.
  • Responses were seen in 10 of 46 (22%) patients with ovarian, oesophageal, small-cell lung cancer, and melanoma.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Vascul Pharmacol. 2009 Nov-Dec;51(5-6):337-43 [19737629.001]
  • [Cites] Eur J Cancer. 2000 Sep;36(14):1833-43 [10974632.001]
  • [Cites] Radiother Oncol. 2001 Aug;60(2):155-61 [11439210.001]
  • [Cites] Int J Cancer. 2002 May 1;99(1):1-6 [11948484.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3408-16 [12067983.001]
  • [Cites] Br J Cancer. 2003 Apr 22;88(8):1160-7 [12698178.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):187s-193s [12743133.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2815-22 [12807934.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2823-30 [12807935.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2831-42 [12807936.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4428-38 [14645433.001]
  • [Cites] Eur J Cancer. 2004 Jan;40(2):284-90 [14728944.001]
  • [Cites] Anticancer Drugs. 1993 Feb;4(1):19-25 [8457709.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1626-34 [10197639.001]
  • [Cites] J Natl Cancer Inst. 2004 Nov 17;96(22):1682-91 [15547181.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1527-33 [15746056.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jul-Aug;16(4):1557-64 [16884365.001]
  • [Cites] Science. 2006 Sep 22;313(5794):1785-7 [16990548.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):211-7 [17448875.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Aug;19(6):443-56 [17459681.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Aug;92(8):2902-9 [17550961.001]
  • [Cites] Anticancer Res. 2000 Jan-Feb;20(1A):229-33 [10769660.001]
  • (PMID = 20389300.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Stilbenes; BG3F62OND5 / Carboplatin; I5590ES2QZ / fosbretabulin; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC2865759
  •  go-up   go-down


95. Pavlick AC, Ott P, Escalon J, Madden K, Yepes E, Staha J, Mendoza S, Gandhi A, Yee H, Liebes L: Survival of advanced melanoma patients with normal LDH treated with oblimersen, temozolomide, and nab-paclitaxel. J Clin Oncol; 2009 May 20;27(15_suppl):9080

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of advanced melanoma patients with normal LDH treated with oblimersen, temozolomide, and nab-paclitaxel.
  • Bcl-2 antisense therapy in combination with dacarbazine was encouraging in advanced melanoma patients(pts) with normal LDH.
  • METHODS: Chemotherapy-naïve advanced melanoma pts (ECOG PS ≤ 2, baseline LDH ≤1.1 × ULN, measurable disease per RECIST) were enrolled on a phase I/II protocol.
  • CONCLUSIONS: Our data suggest that the combination of OBL, TMZ, and ABX is synergistic in advanced melanoma pts with normal LDH, possibly translating into improved OS compared to prior regimens with dacarbazine ± OBL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962199.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Koffman J, Morgan M, Edmonds P, Speck P, Higginson IJ: Vulnerability in palliative care research: findings from a qualitative study of black Caribbean and white British patients with advanced cancer. J Med Ethics; 2009 Jul;35(7):440-4
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vulnerability in palliative care research: findings from a qualitative study of black Caribbean and white British patients with advanced cancer.
  • AIM: To examine issues of vulnerability in cancer and palliative care research obtained through qualitative interviews.
  • METHOD: Secondary analysis of qualitative data from 26 black Caribbean and 19 white British patients with advanced cancer.

  • MedlinePlus Health Information. consumer health - Cancer--Living with Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19567695.001).
  • [ISSN] 1473-4257
  • [Journal-full-title] Journal of medical ethics
  • [ISO-abbreviation] J Med Ethics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


97. Kumar A, Mhaskar A, Vadaparampil S, Djulbegovic B, Quinn G, Moffitt Fertility Preservation Group: Fertility preservation and timing of cancer treatment. J Clin Oncol; 2009 May 20;27(15_suppl):e20629

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fertility preservation and timing of cancer treatment.
  • : e20629 Background: Cancer survival rates have increased steadily over time and young cancer survivors desire quality of life, including the ability to have a family.
  • Cancer treatments, due to its toxic nature, can permanently or temporarily affect fertility.
  • However, advanced fertility preservation measures are available and should be pursued before toxic chemo or radiation therapy.
  • Evidence from observational studies indicate patients want to be informed of the adverse effects of cancer treatments on their fertility.
  • METHODS: A comprehensive literature search was performed of MEDLINE and Cochrane databases from 1966-2008 for all phase III randomized controlled trials (RCT) comparing early versus late treatment in cancer patients as first line therapy.
  • 3 RCTs assessed the efficacy of early versus deferred treatment in prostate cancer, 3 in multiple myeloma, and 1 each in lung cancer and chronic lymphocytic leukemia (CLL).
  • However, the benefit with early treatment was restricted to prostate cancer(HR=1.21,95%CI 1.09-1.35).
  • There was no survival difference between early and deferred treatment in multiple myeloma (HR=1.11,95%CI 0.67-1.84), CLL (HR=0.89,95%CI 0.49-1.59) or lung cancer (HR=0.95,95%CI 0.72-1.24).
  • Pooled results excluding prostate cancer RCTs did not show a survival benefit with early treatment (HR=0.97,95%CI 0.78-1.21).
  • CONCLUSIONS: The totality of the evidence shows except in prostate cancer, deferment of treatment does not lead to decreased survival, and provides a unique window to oncologists to address the issues related to fertility preservation if desired by patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961594.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Chouaid C, Vergnenègre A, Florentin V, Walzer S: Analysis of the costs of bevacizumab plus cisplatin and gemcitabine versus cetuximab plus vinorelbine and cisplatin in patients with advanced non-small cell lung cancer (NSCLC) in France: Results from a cost modelling study. J Clin Oncol; 2009 May 20;27(15_suppl):e17560

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of the costs of bevacizumab plus cisplatin and gemcitabine versus cetuximab plus vinorelbine and cisplatin in patients with advanced non-small cell lung cancer (NSCLC) in France: Results from a cost modelling study.
  • : e17560 Background: New treatment options for advanced NSCLC can offer improved survival over standard chemotherapy (CT).
  • Bevacizumab (BEV), a humanized monoclonal antibody (MAb) directed against VEGF when combined with CT increases overall survival (median 13.6 months in the AVAiL study) and progression-free survival (PFS) in patients with advanced NSCLC compared with CT alone.
  • METHODS: A Markov model was used to compare drug and administration costs associated with treating advanced NSCLC with either BCG or CVC.
  • CONCLUSIONS: Targeted therapy using BEV is less costly than CTX in France, and therefore, from a budget perspective offers the best value for money approach to improving outcomes in patients with advanced NSCLC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963846.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Hsu C, Lin Z, Lee K, Yeh K, Hsiao C, Shen Y, Chang D, Wang S, Hsu C, Cheng A: A phase II trial of thalidomide plus tegafur/uracil for patients with advanced/metastatic hepatocellular carcinoma (HCC): Final report. J Clin Oncol; 2009 May 20;27(15_suppl):e15533

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of thalidomide plus tegafur/uracil for patients with advanced/metastatic hepatocellular carcinoma (HCC): Final report.
  • : e15533 Background: Thalidomide (T) is an anti-angiogenic agent with modest activity in advanced/metastatic HCC.
  • Metronomic chemotherapy has been shown to have anti-angiogenic and anti-cancer effect in preclinical and clinical models.
  • This study evaluated the efficacy and safety of the combination of T and metronomic UFT as first-line therapy for advanced HCC.
  • METHODS: Patients (Pts) with advanced HCC not treatable by surgery or other loco-regional therapies received T 100mg bid and UFT 125mg/m<sup>2</sup> (based on tegafur) bid continuously.
  • CONCLUSIONS: The combination of T with metronomic UFT is a well-tolerated regimen with moderate activity for advanced HCC, and worth further exploration in pts with CLIP score ≤3.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962317.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Sangha R, Ho C, Beckett L, Lau DH, Lara PN, Davies AM, Mack PC, Koslan GM, Holland WS, Gandara DR: Dual epidermal growth factor receptor (EGFR) inhibition: Phase I study combining cetuximab (C225) and erlotinib (E) in advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):3552

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dual epidermal growth factor receptor (EGFR) inhibition: Phase I study combining cetuximab (C225) and erlotinib (E) in advanced solid tumors.
  • METHODS: Patients (pts) with advanced solid tumors were enrolled using a standard phase I dose escalation design.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961369.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement